Document:

EX-4.2

 Exhibit 4.2 
  

 
 AURA BIOSCIENCES, INC. 

FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

March 18, 2021 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 SECTION 1
	 	 DEFINITIONS
	  	 	3	 
			
	 1.1
	 	Certain Definitions	  	 	3	 
			
	 SECTION 2
	 	 REGISTRATION RIGHTS
	  	 	9	 
			
	 2.1
	 	Demand Registration	  	 	9	 
	 2.2
	 	Company Registration	  	 	11	 
	 2.3
	 	Registration on Form S-3	  	 	12	 
	 2.4
	 	Expenses of Registration	  	 	13	 
	 2.5
	 	Registration Procedures	  	 	13	 
	 2.6
	 	Indemnification	  	 	16	 
	 2.7
	 	Information by Holder	  	 	18	 
	 2.8
	 	Restrictions on Transfer	  	 	18	 
	 2.9
	 	Rule 144 Reporting	  	 	20	 
	 2.10
	 	Market Stand-Off Agreement	  	 	21	 
	 2.11
	 	Delay of Registration	  	 	21	 
	 2.12
	 	Limitations on Subsequent Registration Rights	  	 	21	 
	 2.13
	 	Termination of Registration Rights	  	 	22	 
			
	 SECTION 3
	 	 COVENANTS OF THE COMPANY
	  	 	22	 
			
	 3.1
	 	Basic Financial Information	  	 	22	 
	 3.2
	 	Inspection Rights	  	 	23	 
	 3.3
	 	Confidentiality	  	 	23	 
	 3.4
	 	Insurance	  	 	24	 
	 3.5
	 	Employee Agreements	  	 	24	 
	 3.6
	 	Employee Stock	  	 	25	 
	 3.7
	 	Matters Requiring Preferred Director Approval	  	 	25	 
	 3.8
	 	Board Matters	  	 	26	 
	 3.9
	 	Observer Rights	  	 	26	 
	 3.10
	 	Successor Indemnification	  	 	27	 
	 3.11
	 	Expenses of Counsel	  	 	27	 
	 3.12
	 	Indemnification Matters	  	 	27	 
	 3.13
	 	Properties, Business and Insurance	  	 	28	 
	 3.14
	 	Right to Conduct Activities	  	 	28	 
	 3.15
	 	FCPA	  	 	29	 
	 3.16
	 	Defense Production Act	  	 	29	 
	 3.17
	 	Termination of Covenants	  	 	29	 
	 3.18
	 	Material Non-Public Information	  	 	29	 
			
	 SECTION 4
	 	 RIGHT OF FIRST REFUSAL
	  	 	30	 
			
	 4.1
	 	Right of Refusal of the Investors	  	 	30	 
			
	 SECTION 5
	 	 MISCELLANEOUS
	  	 	33	 
			
	 5.1
	 	Additional Investors; Successor and Assigns	  	 	33	 
	 5.2
	 	Amendment; Waiver	  	 	33	 

  
 i 

							
	 5.3
	 	Notices	  	 	34	 
	 5.4
	 	Governing Law	  	 	34	 
	 5.5
	 	Entire Agreement	  	 	35	 
	 5.6
	 	Delays or Omissions	  	 	35	 
	 5.7
	 	Severability	  	 	35	 
	 5.8
	 	Titles and Subtitles	  	 	35	 
	 5.9
	 	Counterparts	  	 	35	 
	 5.10
	 	Execution and Delivery	  	 	35	 
	 5.11
	 	Further Assurances	  	 	36	 
	 5.12
	 	Aggregation of Stock	  	 	36	 
	 5.13
	 	Effect on Prior Agreement	  	 	36	 

  
 ii 

 AURA BIOSCIENCES, INC. 

FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 18, 2021,
by and among Aura Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”). Unless
otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1. 
 RECITALS

 WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of Series A Convertible Preferred
Stock of the Company, par value $0.00001 per share (“Series A Preferred Stock”), Series A-1 Convertible Preferred Stock of the Company, par value $0.00001 per share (“Series A-1 Preferred Stock”), Series A-2 Convertible Preferred Stock of the Company, par value $0.00001 per share (“Series
A-2 Preferred Stock”), Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series D-1 Preferred Stock and/or Series D-2 Preferred Stock and possess registration rights, information rights, rights of first offer, and other rights pursuant to a Fourth Amended
and Restated Investors’ Rights Agreement dated as of April 1, 2019 by and among the Company and such Investors, as amended on June 25, 2020 (the “Prior Agreement”); and 

WHEREAS, the Existing Investors include holders who constitute the Required Holders (as defined in the Prior Agreement) and who hold a
majority of the outstanding shares of Junior Preferred Stock and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior
Agreement; and 
 WHEREAS, certain of the Investors are parties to that certain Series E Convertible Preferred Purchase Agreement,
under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, the Existing Investors described above and the Company. 

NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement shall be amended and restated in its entirety by this
Agreement, and the parties to this Agreement further agree as follows: 
 SECTION 1 

DEFINITIONS 
 1.1
Certain Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 
 (a)
“Affiliate” shall mean, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner,
limited partner, managing member, member, employee, officer or director of such Person or any venture capital or other investment fund now or hereafter existing that is controlled by or under common control with one or more general partners or
managing members of, or shares the same management or advisory company with, such Person. 

 (b) “Affiliated Fund” shall have the meaning set forth in
Section 2.8(a)(iii) hereof. 
 (c) “Board” or “Board of Directors” shall mean
the board of directors of the Company. 
 (d) “Commission” shall mean the U.S. Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act. 
 (e) “Class A Common Stock” shall
mean the Company’s Class A Common Stock, par value $0.00001 per share, of the Company. 
 (f) “Class B
Common Stock” means shares of the Company’s Class B common stock, par value $0.00001 per share. 
 (g) “Common
Stock” means, collectively, shares of the Company’s Class A Common Stock and Class B Common Stock. 
 (h)
“Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

(i) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and
the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (j) “Exempted Registration”
shall mean a registration relating solely to employee benefit plans, a registration relating to the offer and sale of non-convertible debt securities, a registration relating to a corporate reorganization or
other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales. 
 (k) “Fund
Investor” shall mean each of Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP, and Advent Life Sciences LLP, Advent Life Sciences Fund I LP
(collectively, “Advent”), Chiesi Ventures, LP (“Chiesi”), Columbus Innvierte Life Science F.C.R. (“Columbus”), Ysios BioFund II Innvierte F.C.R. (“Ysios”), Lundbeckfond Invest A/S
(“LV”), Arix Bioscience Holdings Limited (“Arix”), Medicxi Growth I LP, Medicxi Growth Co Invest I LP (together with Medicxi Growth I LP, “Medicxi”), Citadel Multi-Strategy Equities Master Fund Ltd.
(together with its Affiliates, “Surveyor”), Matrix Capital Management Master Fund, LP (“Matrix”), Rock Springs Capital Master Fund LP, Four Pines Master Fund LP and their respective Affiliates (including Affiliated
Funds). 
 (l) “GAAP” shall have the meaning set forth in Section 3.1(a) hereof. 

  
 4 

 (m) “Holder” shall mean: (i) any Investor that holds Registrable
Securities and (ii) any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section 5.1 of this Agreement;
provided, however, that for purposes of this Agreement, a record holder of shares of Preferred Stock convertible into such Registrable Securities shall be deemed to be the Holder of such Registrable Securities; provided,
further, that the Company shall in no event be obligated to register shares of Preferred Stock, and also provided that Holders of Registrable Securities will not be required to convert their shares of Preferred Stock into Common
Stock in order to exercise the registration rights granted hereunder until immediately before the closing of the offering to which the registration relates. 

(n) “Indemnified Party” shall have the meaning set forth in Section 2.6(c) hereof. 

(o) “Indemnifying Party” shall have the meaning set forth in Section 2.6(c) hereof. 

(p) “Initial Public Offering” shall mean the closing of the Company’s first firm commitment underwritten public offering
of Common Stock registered under the Securities Act. 
 (q) “Initiating Holders” shall mean, collectively, Holders who
properly initiate a registration request under this Agreement. 
 (r) “Investors” shall mean the persons and entities
listed on Schedule A hereto. 
 (s) “Junior Preferred Investor” shall mean the holders of Junior Preferred Stock.

 (t) “Junior Preferred Nonpurchasing Holder” shall have the meaning set forth in Section 4.1(d)
hereof. 
 (u) “Junior Preferred Overallotment Notice” shall have the meaning set forth in
Section 4.1(d) hereof. 
 (v) “Junior Preferred Purchasing Holder” shall have the meaning set
forth in Section 4.1(d) hereof. 
 (w) “Junior Preferred Stock” shall mean collectively, all
shares of Series A Preferred Stock, Series A-1 Preferred Stock and Series A-2 Preferred Stock. 

(x) “Key Employee” shall mean any executive-level employee (including division director and vice-president-level positions)
as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Series E Purchase Agreement). 

  
 5 

 (y) “Major Investor” shall mean any Investor that, individually or together
with such Investor’s Affiliates, holds at least 500,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and each
Person to whom any of the rights of any such Investor are assigned pursuant to Section 5.1. 
 (z) “New Securities”
shall have the meaning set forth in Section 4.1(f) hereof. 
 (aa) “Person” shall mean any
individual, corporation, partnership, trust, limited liability company, association or other entity. 
 (bb) “Preferred
Director” shall mean the (1) director elected by the holders of the outstanding Series C Preferred Stock (the “Series C Director”), the one (1) director elected by the holders of the outstanding Series D Preferred
Stock (the “Series D Director”) and the one (1) director elected by the holders of the outstanding Series E Preferred Stock pursuant to the Voting Agreement (the “Series E Director”). 

(cc) “Preferred Director Majority” shall mean the majority of the Preferred Directors. 

(dd) “Preferred Stock” shall mean, collectively, all shares of Junior Preferred Stock and Senior Preferred Stock. 

(ee) “Qualified Public Offering” shall have the meaning set forth in the Restated Certificate. 

(ff) “Registrable Securities” shall mean: (i) shares of Common Stock issuable or issued pursuant to the conversion of
the Shares, (ii) shares of Common Stock issued or issuable (directly or indirectly) upon conversion of any capital stock of the Company owned or later acquired by the Investors and (iii) any Common Stock issued as a dividend or other
distribution with respect to or in exchange for or in replacement of the shares referenced in (i) or (ii) above; provided, however, that Registrable Securities shall not include any shares of Common Stock described in clauses (i),
(ii) or (iii) above (A) which have previously been registered, and sold to the public through a registration statement, (B) which have been sold in a transaction exempt from the registration and prospectus delivery requirements of the
Securities Act so that all transfer restrictions and restrictive legends with respect thereto were able to be removed upon the consummation of such sale or (C) which have been sold in a private transaction in which the transferor’s rights
under this Agreement are not validly assigned in accordance with this Agreement. 
 (gg) The terms “register,”
“registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the
declaration or ordering of the effectiveness of such registration statement. 
 (hh) “Registration Expenses” shall mean all
expenses incurred by the Company in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, accounting fees, escrow fees, fees and disbursements of
counsel for the Company, fees and disbursements of one special counsel for the Holders (selected by the Required Preferred Holders), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such
registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the compensation of regular employees of the Company, which shall be paid in any event by the Company. 

  
 6 

 (ii) “Required Preferred Holders” means the holders of at least sixty
percent (60%) of the outstanding Senior Preferred Stock of the Company voting together as a single class (as determined on an as-converted basis). 

(jj) “Restated Certificate” shall mean the Company’s Ninth Amended and Restated Certificate of Incorporation, as such
may be further amended and restated from time to time. 
 (kk) “Restricted Securities” shall mean any Registrable
Securities required to bear the first legend set forth in Section 2.8(b) hereof. 
 (ll) “Rock
Springs” shall mean Rock Springs Capital Master Fund LP and Four Pines Master Fund LP. 
 (mm) “Rule 144” shall
mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(nn) “Rule 145” shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended
from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (oo) “Securities Act” shall
mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(pp) “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the
sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of one special counsel to the Holders included in Registration Expenses). 

(qq) “Senior Preferred Investor” shall mean the holders of Senior Preferred Stock. 

(rr) “Senior Preferred Nonpurchasing Holder” shall have the meaning set forth in Section 4.1(b)
hereof. 
 (ss) “Senior Preferred Overallotment Notice” shall have the meaning set forth in
Section 4.1(b) hereof. 
 (tt) “Senior Preferred Purchasing Holder” shall have the meaning set
forth in Section 4.1(b) hereof. 

  
 7 

 (uu) “Senior Preferred Stock” shall mean collectively, all shares of Series
B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 
 (vv) “Series B Preferred
Stock” shall mean Series B Convertible Preferred Stock of the Company, par value $0.00001 per share, and shares of Series B Convertible Preferred Stock issuable (whether or not yet issued) upon exercise of the Warrants (as defined in the
Series B Purchase Agreement). 
 (ww) “Series B Purchase Agreement” shall mean that certain Amended and Restated Series B
Convertible Preferred Stock Purchase Agreement, dated on or about March 31, 2016, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. 

(xx) “Series C Preferred Stock” shall mean, collectively: the (i) Series C-1
Preferred Stock and (ii) Series C-2 Preferred Stock. 
 (yy) “Series C-1 Preferred Stock” means shares of the Company’s Series C-1 Convertible Preferred Stock, par value $0.00001 per share. 

(zz) “Series C-2 Preferred Stock” means shares of the Company’s Series C-2 Convertible Preferred Stock, par value $0.00001 per share. 
 (aaa) “Series C Purchase
Agreement” shall mean that certain Series C Convertible Preferred Stock Purchase Agreement, dated as of December 20, 2017, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or
rested from time to time. 
 (bbb) “Series D Preferred Stock” means collectively, the (i) Series D-1 Preferred Stock and (ii) Series D-2 Preferred Stock. 

(ccc) “Series D-1 Preferred Stock” means shares of the Company’s Series D-1 Convertible Preferred Stock, par value $0.00001 per share. 
 (ddd) “Series D-1 Purchase Agreement” shall mean that certain Series D-1 Convertible Preferred Stock Purchase Agreement, dated as of April 1, 2019, by and among the Company
and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. 
 (eee) “Series D-2 Preferred Stock” means shares of the Company’s Series D-2 Convertible Preferred Stock, par value $0.00001 per share. 

(fff) “Series D-2 Purchase Agreement” shall mean that certain Series D-2 Convertible Preferred Stock Purchase Agreement, dated as of June 25, 2020, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to
time 
 (ggg) “Series E Preferred Stock” shall mean Series E Convertible Preferred Stock of the Company, par value $0.00001
per share. 

  
 8 

 (hhh) “Series E Purchase Agreement” shall mean that certain Series E
Convertible Preferred Stock Purchase Agreement, dated as of March 18, 2021, by and among the Company and the Investors named therein, as such may be amended, modified, supplemented or rested from time to time. 

(iii) “Shares” shall mean: (i) the Preferred Stock and (ii) any securities issued with respect to the foregoing
upon any stock split, stock dividend, recapitalization, or similar event or upon any conversion of the Preferred Stock. 
 SECTION 2

 REGISTRATION RIGHTS 

2.1 Demand Registration. 

(a) Demand for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall
receive from Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to at least twenty-five percent (25%) of the Registrable Securities having an aggregate offering price to the
public of not less than Five Million Dollars ($5,000,000) (such request shall state the number of shares of Registrable Securities to be disposed of by such Initiating Holders), the Company shall: 

(i) within ten (10) days give written notice of the proposed registration to all other Holders; and 

(ii) as soon as practicable, file and effect such registration (including, without limitation, filing post-effective amendments, appropriate
qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified
in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by the Company within twenty (20) days after such written notice
from the Company is mailed; provided that the Company shall file the registration statement within sixty (60) days of the receipt of the request from the Initiating Holders. 

(b) Limitations on Demand Registration. The Company shall not be obligated to effect, or to take any action to effect, any such
registration pursuant to this Section 2.1: 
 (i) Prior to the earlier of: (a) three (3) years after the date
of this Agreement, or (b) six (6) months following the closing of the Initial Public Offering; 
 (ii) In any particular jurisdiction
in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be
required by the Securities Act; 
 (iii) After the Company has initiated two (2) such registrations pursuant to this
Section 2.1 (counting for these purposes only registrations which have been declared or ordered effective and pursuant to which not less than all of the Registrable Securities that Holders have requested to be included in
such registrations are actually included and sold in such registrations); or 

  
 9 

 (iv) During the period starting with the date sixty (60) days prior to the
Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a Company-initiated registration; provided that the Company is actively employing, in good
faith, commercially reasonable efforts to cause such registration statement to become effective. 
 (c) Deferral. If: (i) in the
good faith judgment of the Board of Directors, the filing of a registration statement covering the Registrable Securities would be materially detrimental to the Company and the Board of Directors concludes, as a result, that it is in the best
interests of the Company to defer the filing of such registration statement at such time, and (ii) the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment of the
Board of Directors, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement,
then (in addition to, the limitations set forth in Section 2.1(b)(iv) above), the Company shall have the right to defer such filing for a period of not more than sixty (60) days after receipt of the request of the
Initiating Holders, and, provided further, that the Company shall not defer its obligation in this manner more than once in any twelve month period and provided further, the Company shall not register any securities for
its own account or that of any other stockholder during such sixty (60) day period other than an Exempted Registration. 
 (d)
Underwriting. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this
Section 2.1 and the Company shall include such information in the written notice referred to in Section 2.1(a)(i). In such event, the right of any Holder to include all or any portion of its
Registrable Securities in a registration pursuant to this Section 2.1 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities to the
extent provided herein. If the Company shall request inclusion in any registration pursuant to Section 2.1 of securities being sold for its own account, or if other persons shall request inclusion in any registration
pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other
persons in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section (including Section 2.10).
The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such
underwriting by the Initiating Holders, subject to the reasonable approval of the Company. 
 Notwithstanding any other provision of this
Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included
shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. In no event shall Registrable
Securities be excluded from such registration unless all other stockholders’ securities (including securities for the account of the Company) have been first excluded. 

  
 10 

 If a person who has requested inclusion in such registration as provided above does not
agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriters or the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any
Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration
was previously reduced as a result of marketing factors pursuant to this Section 2.1(d), then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to
include additional Registrable Securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion, as set forth above. 

2.2 Company Registration. 

(a) Company Registration. If the Company shall determine to register any of its securities either for its own account or the account of
a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3 or an Exempted Registration, the Company shall: 

(i) within ten (10) days give written notice of the proposed registration to all Holders; and 

(ii) include in such registration (and any related qualification under blue sky laws or other compliance), except as set forth in
Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received by the Company within twenty
(20) days after such written notice from the Company is delivered. Such written request may specify all or a part of a Holder’s Registrable Securities. If a Holder decides not to include all of its Registrable Securities in any
registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the
Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 
 (b) Underwriting. If the
registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In
such event, the right of any Holder to registration pursuant to this Section 2.2(b) shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable
Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders of securities of the Company with registration rights
to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. 

  
 11 

 Notwithstanding any other provision of this Section 2.2, if the
underwriters advise the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be
included in the registration and underwriting. In no event shall any Registrable Securities be excluded from such registration and underwriting unless all other stockholders’ securities have been first excluded. In the event that the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such registration and underwriting, then the Registrable Securities that are included in such registration and underwriting shall
be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no
event shall the amount of securities of the selling Holders included in the registration and underwriting be reduced below thirty percent (30%) of the total amount of securities included in such registration and underwriting (other than in the case
of the Initial Public Offering). 
 If a person who has requested inclusion in such registration as provided above does not agree to the
terms of any such underwriting, such person shall also be excluded therefrom by written notice from the Company or the underwriter. The securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 
 (c) Right to Terminate
Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to
include securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.4. 

2.3 Registration on Form S-3. 

(a) Request for Form S-3 Registration. If the Company is then qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject to the conditions set forth in this Section 2.3, if the Company shall receive from
Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration on Form S-3 or any similar short form registration statement with respect to all or part of the
Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed-of-and the intended methods of disposition of such shares
by such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by Section 2.1(a)(i) and (ii); provided, that in the case of a registration pursuant to this
Section 2.3, the Company shall file the registration statement within forty-five (45) days of the receipt of the request from the Initiating Holders. 

(b) Limitations on Form S-3 Registration. The Company shall not be obligated to effect, or take
any action to effect, any such registration pursuant to this Section 2.3: 
 (i) In the circumstances described in
either Sections 2.1(b)(ii) or 2.1(b)(iv); 

  
 12 

 (ii) If the Initiating Holders, together with the holders of any other securities of the
Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less than Three Million Dollars
($3,000,000); or 
 (iii) If the Company has effected two (2) registrations pursuant to Section 2.3 at any
time within the twelve (12) month period immediately preceding the date of the written request from the Initiating Holders described in Section 2.3(a). 

(c) Deferral. The provisions of Section 2.1(c) shall apply to any registration pursuant to this
Section 2.3. 
 (d) Underwriting. If the Initiating Holders requesting registration under this
Section 2.3 intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.1(d) shall apply to such registration. Notwithstanding
anything contained herein to the contrary, registrations effected pursuant to this Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to Section 2.1.

 2.4 Expenses of Registration. All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1,
2.2 and 2.3 hereof shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if
the registration request is subsequently withdrawn at the request of the Holders of at least a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering
conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so
registered), unless the Holders of at least a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 2.1(a); and provided further, however,
that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with
reasonable promptness after learning of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 2.1 or 2.3. All Selling
Expenses shall be borne pro rata by the selling Holders based on the number of Registrable Securities requested to be so registered. 
 2.5
Registration Procedures. In the case of each registration effected by the Company pursuant to Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the
completion thereof. At its expense, the Company shall: 
 (a) Prepare and file with the Commission a registration statement with respect to
such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and keep such registration effective for a period ending on the earlier of the date which is one hundred twenty
(120) days from the effective date of the registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; provided, however, that (i) such
one hundred twenty (120) day period shall be extended for a period of time equal to the period the 

  
 13 

 
Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any
registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable Commission rules, such one hundred twenty
(120) day period shall be extended for up to 12 months, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection (a) above;
provided further that in connection with any registration on Form S-3 pursuant to Section 2.3 above, the Company agrees to timely file all reports required under the
Exchange Act in order to maintain the right to continue to use such Form S-3 and to maintain such registration in effect; 

(c) Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any amendment
of or supplement to the prospectus as required by the Securities Act and other documents, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) Use commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) Notify each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a
material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and furnish to such Holder a
reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; 

(f) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 14 

 (g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each
securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 
 (h) Otherwise use its
commercially reasonable efforts to comply with all applicable rules and regulations of the Commission; 
 (i) In connection with any
underwritten offering pursuant to a registration statement filed pursuant to Section 2.1 hereof, enter into an underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock,
provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such underwriting shall also enter into and perform its obligations under such an
agreement; 
 (j) Use its reasonable best efforts to furnish, at the request of any Holder requesting registration of Registrable Securities
pursuant to this Section 2, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 2, if such securities
are being sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public
offering and reasonably satisfactory to a majority in interest of Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities, and (ii) a letter dated such date,
from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority
in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; 

(k) Promptly make available for inspection by the selling Holders, any underwriter participating in any disposition pursuant to such
registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the
Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with any such registration statement; 

(l) Notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (m) After such
registration statement becomes effective, notify each selling Holder of any request by the Commission that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

  
 15 

 2.6 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, each of its officers, directors,
stockholders, members and partners, legal counsel, and accountants and each person controlling such Holder within the meaning of the Securities Act or the Exchange Act, with respect to which registration, qualification, or compliance has been
effected pursuant to this Section 2, and each underwriter, if any, and each person who controls within the meaning of the Securities Act or the Exchange Act any underwriter, against all expenses, claims, losses, damages,
and liabilities (or actions, proceedings, or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus,
offering circular, or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance; (ii) any omission (or alleged omission) to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading; or (iii) any violation (or alleged violation) by the Company or any of its agents or affiliates of the Securities Act, the Exchange Act, any state
securities laws or any rule or regulation thereunder applicable to the Company, and the Company will reimburse each such Holder, each of its officers, directors, stockholders, members, partners, legal counsel, and accountants and each person
controlling such Holder, each such underwriter, and each person who controls any such underwriter, for any legal and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage,
liability, or action as they are incurred; provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based
upon written information furnished to the Company and stated to be specifically for use therein by such Holder, any of such Holder’s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such
underwriter or any person who controls any such underwriter; and provided further that, the indemnity agreement contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld or delayed). 

(b) To the extent permitted by law, each selling Holder, severally and not jointly, if Registrable Securities held by such Holder are included
in the securities as to which such registration, qualification, or compliance is being effected, will indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel, and accountants and each underwriter, if any, of
the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other selling Holder, and each of their officers,
directors, stockholders, members and partners, and each person controlling each other selling Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i) any untrue statement (or
alleged untrue statement) of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document (including any related registration statement, notification, or the like)
incident to any such registration, or (ii) any omission (or alleged omission) to state therein a material fact required to 

  
 16 

 
be stated therein or necessary to make the statements therein not misleading, and such Holder will reimburse the Company and other selling Holders, directors, officers, stockholders, members,
partners, legal counsel, and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action as they are
incurred, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in
reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts
paid in settlement of any such claims, losses, damages, or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided that in
no event shall any indemnity or contribution under this Section 2.6 exceed the net proceeds from the offering received by such Holder. 

(c) Each party entitled to indemnification under this Section 2.6 (the “Indemnified Party”) shall
give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying
Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the
Indemnified Party (whose approval shall not be unreasonably withheld); provided, further, however, that an Indemnified Party (together with all other Indemnified Parties that may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual
or potential differing interests between such Indemnified Party and any other party represented by such counsel in such proceeding; and provided further that the failure of any Indemnified Party to give notice as provided herein shall
not relieve the Indemnifying Party of its obligations under this Section 2.6, to the extent such failure is not materially prejudicial to the Indemnifying Party’s ability to defend such action. No Indemnifying Party,
in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably
request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 
 (d)
In any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.6 but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.6 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.6, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall 

  
 17 

 
contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative
fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable
considerations; provided, however, that no contribution by any Holder, when combined with any amounts paid by such Holder pursuant to Section 2.6(b), shall exceed the net proceeds from the offering received by
such Holder. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided,
however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement,
and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.6 shall survive the completion of any offering of Registrable Securities in a registration statement, and otherwise shall survive the termination of this Agreement. 

2.7 Information by Holder. Each Holder of Registrable Securities shall furnish to the Company such information regarding such Holder
and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this
Section 2. 
 2.8 Restrictions on Transfer. 

(a) The Holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section 2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and
until (x) the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without
limitation, this Section 2.8 and Section 2.10, and (y): 
 (i) There is then in effect a
registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 18 

 (ii) Such Holder shall have given prior written notice to the Company of such Holder’s
intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and, if requested by the Company, such Holder shall have furnished the Company, at such
Holder’s expense, with (A) an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Restricted Securities under the Securities Act or (B) a “no
action” letter from the Commission to the effect that the transfer of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto or (C) any other
evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted
Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice delivered by the Holder to the Company. It is agreed that the Company will not require opinions of counsel or “no action”
letters for transactions made pursuant to Rule 144. 
 (iii) Notwithstanding the provisions of subsections (a)(i) and (a)(ii) above,
no such registration statement or opinion of counsel or “no action” letter shall be necessary for: (A) a transfer by a Holder to any of its Affiliates (including an affiliated fund managed by the same manager or managing member or
general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company, each an “Affiliated Fund”); (B) a transfer by a
Holder that is a partnership, limited liability company or corporation to a partner, limited partner, retired partner, member, retired member or stockholder of a Holder; (C) a transfer by gift, will or intestate succession of any partner to his
or her spouse or to the siblings, lineal descendants or ancestors of such partner or his or her spouse; (D) any transfer by a Holder in connection with a Sale of the Company (as defined in the Fifth Amended and Restated Voting Agreement of even
date herewith by and among the Investors, the holders of Common Stock party thereto and the Company (the “Voting Agreement”)); or (E) the transfer by a Holder exercising its co-sale
rights under the Fifth Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith by and among the Company and the Investors and certain other stockholders named therein (the
“ROFR and Co-Sale Agreement”), if in each transfer under clauses (A), (B) or (C), the prospective transferee agrees in all such instances in writing to be subject to the terms hereof to the
same extent as if he or she were an original Holder hereunder. 
 (b) Each certificate representing Registrable Securities shall (unless
otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SHARES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION

  
 19 

 
THEREFROM. THE ISSUER OF THESE SHARES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND
RESALE, INCLUDING A LOCK-UP PERIOD OF UP TO 180 DAYS (SUBJECT TO EXTENSION) IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTOR RIGHTS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL
OFFICE OF THE COMPANY. 
 The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent
of the Restricted Securities in order to implement the restrictions on transfer established in this Section 2.8. 

(c) The first legend referring to federal and state securities laws identified in Section 2.8(b) hereof stamped on a
certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities shall be removed and the Company shall issue a certificate without such legend to the holder of such
Restricted Securities if (i) such securities are registered under the Securities Act; or (ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a public sale or transfer of
such securities may be made without registration under the Securities Act; or (iii) such holder provides the Company with reasonable assurances, which may, at the option of the Company, include an opinion of counsel reasonably satisfactory to
the Company, that such securities can be sold pursuant to Rule 144 under the Securities Act. 
 2.9 Rule 144 Reporting. With a view
to making available the benefits of certain rules and regulations of the Commission that may permit the sale of the Restricted Securities to the public without registration or pursuant to a registration on Form
S-3, the Company agrees to: 
 (a) Make and keep available adequate current public information
regarding the Company available as those terms are understood and defined in Rule 144 under the Securities Act, at all times from and after the effective date of the first registration under the Securities Act filed by the Company for an offering of
its securities to the general public; 
 (b) Use commercially reasonable efforts to file with the Commission in a timely manner all reports
and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and 

(c) So long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective date of the first registration statement filed by the Company for an offering of its

  
 20 

 
securities to the general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so
filed by the Company and such other information as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration (at any time after it has become
subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies). 

2.10 Market Stand-Off Agreement. If requested by the Company and the managing underwriter of
Common Stock (or other securities) of the Company, each Holder hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of grant any option for the purchase of, or enter into any hedging or similar transaction with
the same economic effect as a sale, of any Common Stock (or other securities) of the Company held by such Holder immediately prior to the effective date for the registration statement for the Initial Public Offering (other than any shares included
in the registration) during the one hundred and eighty (180) day period following the effective date of the Initial Public Offering. The foregoing provisions of this Section 2.10 shall not apply to transactions
(including, without limitation, any swap, hedge or similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the Initial Public Offering or securities acquired in open market or other transactions from and
after the Initial Public Offering or that otherwise that do not involve or relate to shares of Common Stock owned by a Holder prior to the IPO, shall be applicable to the Holders only if all officers, directors, and stockholders individually and
together with their Affiliates owning one percent (1%) or more of the outstanding Common Stock are subject to the same restrictions and provided, in addition, the Company will use commercially reasonable efforts to obtain the consent of the
managing underwriter for earlier release of market stand-off and transfer restrictions on a portion of the Holders’ Common Stock and if the Company or any underwriter of the Initial Public Offering waives
or terminates any market stand-off or transfer restrictions imposed on any holder of securities of the Company, then such waiver or termination shall be granted to all Holders subject to market stand-off or transfer restrictions hereby, pro rata based on the number of shares of Common Stock beneficially held by such other holder and the Holders hereby. The underwriters in connection with such registration
are intended third-party beneficiaries of this Section 2.10 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. The Company may impose stop-transfer
instructions and may stamp each such certificate with the second legend set forth in Section 2.8(b) hereof with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end
of such one hundred eighty (180) day period. Each Holder agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of this Section 2.10. 

2.11 Delay of Registration. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any registration
as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.12 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Required Preferred Holders, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which are pari passu
with or senior to the registration rights granted to the Holders hereunder. 

  
 21 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion in any registration pursuant to Section 2.1, 2.2 or 2.3 shall terminate on the earlier of: (i) five (5) years after the closing of the Company’s Initial Public Offering;
(ii) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, in which the consideration received by the Investors in such Deemed Liquidation Event is in the form of cash and/or
publicly traded securities, or if the Investors receive registration rights from the acquiring company or other successor to the Company reasonably comparable to those set forth in this Section 2; and (iii) such time
as Rule 144 or another similar exemption under the Securities Act is available for the sale of all such Holder’s shares without limitation during a three-month period without registration. 

SECTION 3 
 COVENANTS OF
THE COMPANY 
 The Company hereby covenants and agrees, as follows: 

3.1 Basic Financial Information. Provided that any of the Preferred Stock originally issued by the Company or the Registrable Securities
remain outstanding, the Company shall deliver to each Major Investor the following financial information: 
 (a) as soon as practicable, but
in any event within ninety (90) days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a
statement of cash flows for such year, plus, where applicable, comparisons to the annual budget and operating plan approved by the Board of Directors; such year-end financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), and audited and certified by an independent public accounting firm selected by the Board of Directors; 

(b) as soon as practicable, but in any event within thirty (30) days after the end of each of the first three quarters of each fiscal
year of the Company, an unaudited income statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, plus, where applicable, quarterly comparisons to the annual budget and
operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP)
and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment; 

(c) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement and
statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, plus, where applicable, monthly comparisons to the annual budget and operating plan approved by the Board
of Directors; such unaudited financial statements to be prepared in accordance with GAAP and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to
year-end audit adjustment; 

  
 22 

 (d) as soon as practicable, but in any event within the thirty (30) day period prior to
the commencement of each new fiscal year of the Company, an annual budget and operating plan for such fiscal year as approved by the Board of Directors; 

(e) as soon as practicable, but in any event within thirty (30) days of the end of each fiscal quarter, an updated capitalization table,
certified by the Treasurer of the Company; and 
 (f) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any
subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries. 
 3.2 Inspection Rights. Provided that any of the Preferred Stock originally issued
by the Company or the Registrable Securities remain outstanding, the Company will afford to each Major Investor reasonable access during normal business hours to all of the Company’s properties, books and records. Major Investors may exercise
their rights under this Section 3.2 only for purposes reasonably related to their interests as a stockholder. 

3.3 Confidentiality. The Company shall not be required to comply with any inspection rights of Section 3 in
respect of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or holder of more than ten percent (10%) of a competitor (provided that neither the Fund Investors nor a financial investment
firm or collective investment vehicle (including any venture capital fund) shall be deemed to be a competitor of the Company by virtue of its ownership of a portfolio company that competes with the Company), nor shall the Company be obligated to
disclose any information which the Board of Directors determines in good faith is attorney-client privileged and should not, therefore, be disclosed. Each Holder agrees that it will not use any information received by it pursuant to this Agreement
in violation of the Exchange Act or reproduce, disclose or disseminate such information to any other person other than (i) its employees, agents or partners having a need to know the contents of such information, and its attorneys, consultants,
and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Holder, if such prospective
purchaser agrees to be bound by the provisions of this Section 3.3; (iii) to any existing partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that
such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, (iv) to the extent required in connection with any

  
 23 

 
routine or periodic examination or similar process by any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential information obtained from
the Company pursuant to the terms of this Agreement, including, without limitation, quarterly or annual reports or (v) as may otherwise be required by law, provided that, with respect to clauses (iii) and (v), the Holder promptly
notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure; provided further that with respect to clause (iv), the Holder takes reasonable steps to minimize the extent of any such
required disclosure, unless such information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.3 by such Holder), (b) is or has been independently developed or
conceived by the Holder without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Holder by a third party without a breach of any obligation of confidentiality such third party may have to
the Company. The Company acknowledges that certain of the Investors are in the business of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products or
services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise, regardless of whether such enterprise
has products or services that compete with those of the Company. 
 3.4 Insurance. The Company shall use its commercially reasonable
efforts to cause to be maintained, from financially sound and reputable insurers, Directors and Officers liability insurance and term “key-person” insurance on such executives determined by the
Preferred Director Majority, in the amount of at least $5,000,000 and on terms and conditions satisfactory to the Board of Directors, until such time as the Preferred Director Majority determines that such insurance should be discontinued. The key-person policy shall name the Company as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Preferred Director Majority. Each Key Holder (as defined in the ROFR and Co-Sale Agreement) hereby covenants and agrees that, to the extent such Key Holder is named under such key-person policy, such Key Holder will execute and deliver to the
Company, as reasonably requested, a written notice and consent form with respect to such policy. Prior to commencing any clinical trial, the Company shall use its commercially reasonable efforts to obtain, from financially sound and reputable
insurers clinical trial and/or product liability insurance in an amount and on terms and conditions satisfactory to the Preferred Director Majority, and will use commercially reasonable efforts to cause such insurance policy to be maintained until
such time as the Board of Directors determines that such insurance should be discontinued. Immediately prior to the Company’s Initial Public Offering, and subject to further approval by the Preferred Director Majority, the Company will use its
commercially reasonable efforts to increase the coverage amount of its Directors and Officers liability insurance and term “key-person” insurance to an amount commensurate with that of similarly
situated companies in the determination of the Board of Directors. 
 3.5 Employee Agreements. The Company will cause (i) each
person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and
proprietary rights assignment agreement; and (ii) each Key Employee to enter into a one (1) year nonsolicitation agreement in a form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or
otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of the Preferred Director Majority. 

  
 24 

 3.6 Employee Stock. Unless otherwise approved by the Preferred Director
Majority, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option
agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the
remaining shares vesting in equal monthly, quarterly or annual installments over the following three (3) years, and (ii) a market stand-off provision substantially similar to that in
Section 2.10. In addition, unless otherwise approved by the Preferred Director Majority, the Company shall retain a “right of first refusal” on employee transfers until the Company’s Initial Public Offering and
shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 
 3.7 Matters
Requiring Preferred Director Approval. So long as the holders of Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock are entitled to elect a Series C Director, Series D Director or a Series E Director, respectively,
the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Preferred Director Majority: 

(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (b) make, or permit any subsidiary to make, any loan
or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan
approved by the Board of Directors; 
 (c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly,
any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any
investment inconsistent with any investment policy approved by the Board of Directors; 
 (e) otherwise enter into or be a party to any
transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation
any “management bonus” or similar plan providing payments to employees in connection with a Deemed Liquidation Event, except for transactions contemplated by this Agreement and the Series E Purchase Agreement and transactions made in the
ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors; 

  
 25 

 (f) hire, terminate, or change the compensation of the executive officers, including
approving any option grants or stock awards to executive officers; 
 (g) change the principal business of the Company, enter new lines of
business, or exit the current line of business; 
 (h) sell, assign, license, pledge, or encumber material technology or intellectual
property, other than licenses granted in the ordinary course of business; 
 (i) enter into any corporate strategic relationship involving
the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $100,000; or 
 (j) purchase,
lease, license or otherwise acquire for value, or agree or commit to purchase, lease, license or otherwise acquire for value, (i) any material ownership interest, or right to acquire a material ownership interest, in another corporation,
partnership, limited liability company or other entity or (ii) all or substantially of the assets of any (A) such other corporation, partnership, limited liability company or other entity or (B) line of business, division or material
portion of any such other corporation, partnership, limited liability company or other entity. 
 3.8 Board Matters. Unless otherwise
determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall
cause to be established, as soon as practicable after such request, and will maintain, an audit and compensation committee, each of which shall consist solely of non-management directors. Each Committee of the
Board shall be a maximum size of three individuals and shall be comprised solely of Preferred Directors and Independent Directors (as defined in the Voting Agreement). The Series E Director may serve on each Committee of the Board. 

3.9 Observer Rights. The Company shall permit each of Surveyor and LV (each of the foregoing, an “Observer Investor”),
so long as each Observer Investor continues to hold at least twenty-five percent (25%) of the shares (if any) of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock it purchased pursuant to the
Series B Purchase Agreement, Series C Purchase Agreement, Series D-1 Purchase Agreement, Series D-2 Purchase Agreement and Series E Purchase Agreement, respectively, to
designate a designee to attend in person meetings of the Board of Directors (and any committee thereof) in a non-voting, observer capacity (“Observer Rights”). As an observer, notice will be
given to the designee of any scheduled meeting of the Board of Directors (or any committee thereof) at the same time the members of the Board of Directors (or any committee thereof) are given notice, but no change of schedule will be necessary if
the designee is unavailable. Such designee shall be entitled to receive, prior to each meeting of the Board of Directors (or any committee thereof) and at the same time and in the same manner as directors of the Company receive such materials, all
materials sent to members of the Board of Directors (or any committee thereof), subject to the terms of this Section 3.10. Notwithstanding the foregoing, the Company reserves the right to exclude such designee from access
to a meeting of the Board of Directors (or any committee 

  
 26 

 
thereof), any portion thereof, or to any material if the Company believes such exclusion is reasonably necessary (a) to protect the attorney-client privilege, (b) to avoid a potential
conflict of interest on the part of an Observer Investor or (c) to preserve the proper functioning of the Board or the exercise of its fiduciary duties. Each Observer Investor agrees, on behalf of itself and any of its representatives,
including the designee, to hold in confidence and to not use (other than in connection with such Observer Investor’s evaluation of its investment in the Company) or disclose any information provided to or learned by it in connection with its
Observer Rights. This Section 3.10 may not be amended or waived as to any Observer Investor without the written consent of such Observer Investor. 

3.10 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. 
 3.11 Expenses of Counsel. In the event of a transaction which is a Sale of the Company, the reasonable fees and disbursements
of one counsel for the Senior Preferred Investors (“Investor Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a
Sale of the Company, the Company shall obtain the ability to share with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of
memoranda of understanding, letters of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or
when aggregated with others, would constitute the Sale of the Company. The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives
and/or any one or more of the other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the
parties to protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and
substance reasonably acceptable to Investor Counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in
order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to
negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. 
 3.12 Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the Preferred Directors nominated to serve on the Board of Directors by the Senior Preferred Investors (each a “Fund Director”) may have certain rights to
indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their Affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the
indemnitor 

  
 27 

 
of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same
expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties,
fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such
Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for
contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund
Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such
Fund Director against the Company. The Fund Directors and the Fund Indemnitors are intended third-party beneficiaries of this Section 3.13 and shall have the right, power and authority to enforce the provisions of this
Section 3.13 as though they were a party to this Agreement. 
 3.13 Properties, Business and Insurance. The
Company and its subsidiaries shall maintain as to their respective properties and business, with financially sound and reputable insurers, insurance against such casualties and contingencies and of such types and in such amounts as is customary for
companies similarly situated, which insurance shall be deemed by the Company to be sufficient. For so long as any Preferred Director serves on the Board, and for a period of at least six (6) years thereafter, the Company hereby agrees to
(i) provide in the certificate of incorporation and bylaws of the Company for indemnification and reimbursement of expenses of directors and officers to the fullest extent permitted by the General Corporation Law of the State of Delaware or the
general corporation law of the state of its incorporation, as applicable; and (ii) maintain director and officer insurance in an amount described in Section 3.4 on behalf of any person who is or was a director or an
officer of the Company, or is or was serving at the request of the Company as a director or an officer of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by
him or her in any such capacity, or arising out of his or her status as such. 
 3.14 Right to Conduct
Activities. The Company hereby agrees and acknowledges that each Fund Investor is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the
Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, each Fund Investor shall not be liable to the Company for any claim arising
out of, or based upon, (i) the investment by such Fund Investor in any entity competitive with the Company, or the evaluation of a potential investment in any such entity, or (ii) actions taken by any partner, officer or other
representative of such Fund Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect
on the Company; provided that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or
(y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

  
 28 

 3.15 FCPA. The Company represents that it shall not (and shall not permit any of its
subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to,
directly or indirectly, to any third party, including any Non-U.S. Official (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case,
in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their
respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the
FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including,
but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide
responsive information and/or certifications concerning its compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any allegation, voluntary disclosure, investigation,
prosecution or other enforcement action related to the FCPA or any other anti-corruption law. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to
comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 

3.16 Defense Production Act. To the extent that the Company engages in the design, fabrication, development, testing, production or
manufacture of critical technologies within the meaning of the DPA (as defined in the Purchase Agreement), whether because of a new categorization of technology by the U.S. government or otherwise, the Company shall promptly provide written notice
to Surveyor. 
 3.17 Termination of Covenants. The covenants set forth in this Section 3, except for
Sections 3.11 and 3.13, shall terminate and be of no further force or effect (i) immediately before the consummation of the Initial Public Offering or (ii) when the Company first becomes subject to the periodic reporting
requirements of Section 12 or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

3.18 Material Non-Public Information. The Company understands and acknowledges that in the
regular course of Surveyor’s and Rock Springs’ businesses, Surveyor and Rock Springs (and their respective Affiliates) will invest in companies that have issued securities that are publicly traded (each, a “Public
Company”). Accordingly, the Company covenants and agrees that before providing any material non-public information about a Public Company (“Public Company Information”) to Surveyor,
Rock Springs or their representatives (or any of their respective Affiliates), the Company shall provide written notice of such Public Company Information to Surveyor’s compliance officer at SCComplianceAppvl@citadel.com and to Jill

  
 29 

 
Seidman at Rock Springs at jill@rockspringscapital.com, respectively, describing such Public Company Information in reasonable detail. The Company shall not disclose Public Company Information to
Surveyor, Rock Springs or their representatives (or any of their respective Affiliates) without prior written authorization from Surveyor’s and Rock Springs’ compliance officer listed above. In addition, the Company acknowledges and agrees
that in no event shall Surveyor’s or Rock Springs’ (or their respective representatives’) confidentiality and non-use obligations hereunder (including, without limitation, pursuant to
Section 3.9) in any manner be deemed or construed as limiting Surveyor, or Rock Springs’, or their respective representatives (or any of their respective Affiliates) ability to trade any security of a Public Company or any other Person.

 SECTION 4 
 RIGHT OF
FIRST REFUSAL 
 4.1 Right of Refusal of the Investors. 

(a) Provided that any Senior Preferred Stock originally issued by the Company or any of the Registrable Securities remain outstanding, the
Company hereby grants to each Senior Preferred Investor that is a Major Investor a right of first refusal to purchase its pro rata share of New Securities which the Company may, from time to time, propose to sell and issue after the date of this
Agreement. A Major Investor’s pro rata share, for purposes of this right of first refusal, is equal to the ratio of (i) the number of shares of Senior Preferred Stock (as determined on an
as-converted to Common Stock basis) then owned (or subject to warrants owned by) by such Major Investor to (ii) the total number of shares of Senior Preferred Stock (as determined on an as-converted to Common Stock basis) then outstanding immediately prior to issuance of the New Securities, including shares of Series B Preferred Stock subject to outstanding warrants). A Major Investor who chooses
to exercise its right of first refusal may designate as purchasers under such right itself and/or its partners or Affiliates (including Affiliated Funds), in such proportions as it deems appropriate. 

(b) In the event the Company proposes to undertake an issuance of New Securities, it shall give each Major Investor written notice of its
intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Major Investor shall have twenty (20) days after any such notice is mailed or delivered to agree to
purchase such Holder’s pro rata share of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased. If any Major
Investor fails to so agree in writing within such twenty (20) day period to purchase such Holder’s full pro rata share of an offering of New Securities (a “Senior Preferred Nonpurchasing Holder”), then such Senior
Preferred Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of such Senior Preferred Nonpurchasing Holder’s pro rata share of such New Securities that such Senior Preferred Nonpurchasing Holder did not so agree to
purchase. The Company shall promptly give each Major Investor who has timely agreed to purchase such Holder’s full pro rata share of such offering of New Securities (a “Senior Preferred Purchasing Holder”) written notice of the
failure of any Senior Preferred Nonpurchasing Holder to purchase such Senior Preferred Nonpurchasing Holder’s full pro rata share of such offering of New Securities (the “Senior Preferred Overallotment Notice”). Each Senior
Preferred Purchasing Holder shall have a right 

  
 30 

 
of overallotment such that such Senior Preferred Purchasing Holder may agree to purchase a portion of the Senior Preferred Nonpurchasing Holders’ unpurchased pro rata shares of such offering
on a pro rata basis according to the relative pro rata shares of the Senior Preferred Purchasing Holders, at any time within five (5) days after receiving the Senior Preferred Overallotment Notice. 

(c) The Company hereby grants to each Junior Preferred Investor, a right of second refusal to purchase its pro rata share of any New
Securities not so purchased by the Major Investors. A Junior Preferred Investor’s pro rata share, for purposes of this right of first refusal: is equal to the ratio of (i) the number of shares of Common Stock then owned by such Junior
Preferred Investor (on an as-converted basis) to (ii) the total number of shares of Common Stock then owned by all Junior Preferred Investors (on an as-converted
basis). A Junior Preferred Investor who chooses to exercise its right of second refusal may designate as purchasers under such right itself and/or its partners or Affiliates (including Affiliated Funds), in such proportions as it deems appropriate.
Any such sale to such Junior Preferred Investors shall be at a price and upon terms no more favorable than specified in the Company’s notice to Senior Preferred Investors delivered pursuant to Section 4.1(b). 

(d) In the event the Major Investors fail to exercise fully the right of first refusal within the periods described in this
Section 4.1(b), the Company shall give each Junior Preferred Investor written notice of its intention to issue New Securities, describing the type of New Securities, and their price and the general terms upon which the
Company proposes to issue the same. Each Junior Preferred Investor shall have ten (10) days after any such notice is mailed or delivered to agree to purchase such Holder’s pro rata share of such New Securities not purchased by the Major
Investors for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased. If any Junior Preferred Investor fails to so agree in writing within such
ten (10) day period to purchase such Holder’s full pro rata share of an offering of New Securities not purchased by the Senior Preferred Investors (a “Junior Preferred Nonpurchasing Holder”), then such Junior Preferred
Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of such Junior Preferred Nonpurchasing Holder’s pro rata share of such New Securities that such Junior Preferred Nonpurchasing Holder did not so agree to purchase. The
Company shall promptly give each Junior Preferred Investor who has timely agreed to purchase such Holder’s full pro rata share of such offering of New Securities (a “Junior Preferred Purchasing Holder”) written notice of the
failure of any Junior Preferred Nonpurchasing Holder to purchase such Junior Preferred Nonpurchasing Holder’s full pro rata share of such offering of New Securities (the “Junior Preferred Overallotment Notice”). Each Junior
Preferred Purchasing Holder shall have a right of overallotment such that such Junior Preferred Purchasing Holder may agree to purchase a portion of the Junior Preferred Nonpurchasing Holders’ unpurchased pro rata shares of such offering on a
pro rata basis according to the relative pro rata shares of the Junior Preferred Purchasing Holders, at any time within five (5) days after receiving the Junior Preferred Overallotment Notice. 

(e) In the event the Junior Preferred Investors fail to exercise fully the right of second refusal within the periods described in
Section 4.1(d) (the “Election Period”), the Company shall have forty-five (45) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be
closed, if at all, within forty-five (45) 

  
 31 

 
days from the date of said agreement) to sell to any Person or Persons any or all New Securities which have not been subscribed by Investors pursuant to their right of first refusal option set
forth in this Section 4.1. Any such sale to such Person or Persons shall be at a price and upon terms no more favorable to the purchasers thereof than specified in the Company’s notice to Investors delivered pursuant
to Section 4.1. In the event the Company has not sold such unsubscribed New Securities within such forty-five (45) day period following the Election Period, or such forty-five (45) day period following the date of
said agreement, the Company shall not thereafter issue or sell such New Securities without first again offering such New Securities first, to the Major Investors, and second, to the Junior Preferred Investors, in the manner provided in this
Section 4.1. 
 (f) “New Securities” shall mean any capital stock (including Common Stock and/or
Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever (including debt securities) that are, or may become,
exercisable or convertible into capital stock; provided that the term “New Securities” does not include: 
 (i) the
Shares or any shares of Common Stock issuable upon conversion thereof; 
 (ii) Exempted Securities as defined in Article FOURTH, Part C,
Section 4.4.1(h)(i) to (ix) of the Restated Certificate, as such provision is amended, modified, supplemented or replaced; 

(iii) the issuance of Series E Preferred Stock pursuant to the Series E Purchase Agreement; or 

(iv) shares issued pursuant to an Initial Public Offering. 

(g) Notwithstanding anything to the contrary in this Agreement, this Section 4.1 (including, without limitation,
Sections 4.1(c) and (d)) may be amended or waived by a written instrument referencing this Agreement and signed by the Company and the Required Preferred Holders; provided that, in the event of any such waiver and subsequent purchase of New
Securities by an existing Major Investor, then all Major Investors shall have the right, but not the obligation, to purchase such holder’s pro rata share (determined pursuant to Section 4.1(b)) of such New Securities
for the same price and upon the same terms. In addition to the preceding sentence, Section 4.1(c) and (d) may be waived by a written instrument referencing this Agreement and signed by the Company and a majority
of the holders of the Junior Preferred Stock. 
 (h) The right of first refusal granted under this Agreement shall expire and be of no
further force or effect (i) immediately before the consummation of the Initial Public Offering or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or
(iii) upon a Deemed Liquidation Event. 

  
 32 

 SECTION 5 

MISCELLANEOUS 
 5.1
Additional Investors; Successor and Assigns. 
 (a) Notwithstanding anything to the contrary herein, if the Company shall issue
additional shares of its Series E Preferred Stock, any purchaser of such shares may become a party to this Agreement by executing and delivering an adoption agreement to this Agreement, in the form of Attachment A (the “Adoption
Agreement”) and shall be deemed, an “Investor” hereunder and Schedule A shall be amended to include such Investor or permitted transferee. 

(b) The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable
Securities that: (a) after such transfer, holds at least five percent (5%) of the transferring Investor’s shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends,
reverse stock splits, and the like); (b) is an Affiliate of such Holder (including an Affiliated Fund) or a subsidiary, parent, partner, limited partner, retired partner, member, retired member or stockholder of a Holder; or (c) is a family
member of such Holder or trust for the benefit of a such Holder or such Holder’s family members; provided that, in each case, (i) any such transfer or assignment of Registrable Securities is effected in accordance with the terms of
Section 2.8 hereof, and applicable securities laws; (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the
securities with respect to which such registration rights are intended to be transferred or assigned; (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without
limitation the obligations set forth in Section 2.10; and (iv) any such transferee is not engaged in competition with the Company as reasonably determined by the Board of Directors (provided that any such
transferee that is a Fund Investor or a financial investment firm or collective investment vehicle (including any venture capital or other investment fund) shall not be deemed to be engaged in competition with the Company by virtue of its ownership
of a portfolio company that competes with the Company). The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. 
 5.2 Amendment; Waiver. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended,
waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Required Preferred Holders; provided that (i) if such amendment, waiver, discharge or termination (other
than a waiver of Section 4) adversely affects the holders of Junior Preferred Stock in a manner in which the holders of Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require the written
consent of Investors holding at least a majority of the outstanding Junior Preferred Stock (on an as-converted to Common Stock basis), (ii) if such amendment, waiver, discharge or termination adversely affects
the holders of the Series E Preferred Stock in a manner in which the holders of other Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require the written consent of the holders of a majority of
the shares of Series E Preferred Stock then outstanding, (iii) if such amendment, waiver, discharge or termination adversely affects the holders of the Series D Preferred Stock in a manner in which the holders of other Senior Preferred Stock
are not similarly affected, such amendment, modification or waiver shall also require the written consent of the holders of at least seventy percent (70%) of the shares of Series D Preferred Stock then

  
 33 

 
outstanding, (iv) if such amendment, modification or waiver adversely affects the holders of the Series C Preferred Stock in a manner in which the holders of other Senior Preferred Stock are
not similarly affected, such amendment, modification or waiver shall also require the written consent of holders of a majority of the Series C Preferred Stock then outstanding, which majority must include either LV or Arix, and (v) if such
amendment, modification or waiver adversely affects the holders of the Series B Preferred Stock in a manner in which the holders of other Senior Preferred Stock are not similarly affected, such amendment, modification or waiver shall also require
the written consent of holders of at least fifty-seven percent (57%) of the shares of the Company’s Series B Preferred Stock then outstanding. For the avoidance of doubt, the issuance by the Company of any new series of Preferred Stock that
constitutes Senior Preferred Stock or any additional shares of an existing series of Senior Preferred Stock in compliance with Section 4.1 shall not be deemed to adversely affect the holders of Junior Preferred Stock in a
manner in which the holders of Senior Preferred Stock are not similarly affected. Any such amendment, waiver, discharge or termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of all such
securities of the Holder. Each Holder acknowledges that by the operation of this paragraph, the Required Preferred Holders will have the right and power to diminish or eliminate all rights of such Holder under this Agreement, including rights under
Section 4 hereof. 
 5.3 Notices. All notices and other communications required or permitted hereunder
shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or email or otherwise delivered by hand or by messenger addressed: 

(a) if to an Investor, one copy should be sent to the Investor, at the Investor’s address, facsimile number or email address as shown in
the Company’s records, as may be updated in accordance with the provisions hereof, with copies to Edwin C. Pease and Steven Hoffman, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 and Brian P.
Lenihan and Tobin P Sullivan, Choate Hall & Stewart LLP, Two International Place, Boston MA 02110; or 
 (b) if to the Company, one
copy should be sent to Aura Biosciences, Inc., 85 Bolton Street, Cambridge, MA 02140 or at such other address as the Company shall have furnished to the Investors, with a copy to Goodwin Procter LLP, 100 Northern Avenue, Boston MA 02210, Attn:
Danielle Lauzon, Esq. (DLauzon@goodwinlaw.com). 
 Each such notice or other communication shall for all purposes of this Agreement be
treated as effective or having been given when delivered if delivered personally, or, if sent by mail, at the earlier of its receipt or seventy-two (72) hours after the same has been deposited in a
regularly maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid or, if sent by facsimile, upon confirmation of facsimile transfer or, if sent by email, upon confirmation of delivery when directed to the
email address as shown in the Company’s records, as may be updated in accordance with the provisions hereof. 
 5.4 Governing
Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance
with the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 

  
 34 

 5.5 Entire Agreement. This Agreement and the Schedules hereto constitute the full and
entire understanding and agreement between the parties with regard to the subjects hereof and supersedes all prior written or oral agreements and understandings relating to such subject matter. No party hereto shall be liable or bound to any other
party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein. 

5.6 Delays or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to
any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such non-defaulting party, nor shall it be construed to be a
waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement,
must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and not alternative.

 5.7 Severability. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a
valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its
terms. 
 5.8 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and schedules shall, unless otherwise provided, refer to sections and paragraphs hereof and schedules attached hereto. 

5.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties
that execute such counterparts, and all of which together shall constitute one instrument. 
 5.10 Execution and Delivery. A
facsimile, PDF or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party
can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile,
PDF or other reproduction hereof. 

  
 35 

 5.11 Further Assurances. Each party hereto agrees to execute and deliver, by the
proper exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement. 

5.12 Aggregation of Stock. All shares of Registrable Securities held or acquired by affiliated entities or persons or entities under
common investment management or control shall be aggregated together for the purpose of determining the availability of any rights or obligations under this Agreement. 

5.13 Effect on Prior Agreement. Upon the execution and delivery of this Agreement by the Company, the Required Holders (as defined in
the Prior Agreement) and a majority of the outstanding shares of Junior Preferred Stock, the Prior Agreement automatically shall terminate and be of no further force and effect and shall be amended and restated in its entirety as set forth in this
Agreement. 
 [Remainder of Page Intentionally Left Blank] 

  
 36 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	COMPANY:
	
	AURA BIOSCIENCES, INC.
		
	By:	 	/s/ Elisabet de los Pinos
		 	Elisabet de los Pinos, Ph.D., President and CEO

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	MATRIX CAPITAL MANAGEMENT
MASTER FUND, LP

 
			
		
	By:	 	/s/ David Goel

 
			
	Name:	 	David Goel
	Title:	 	Managing General Partner

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.

 
			
		
	By:	 	/s/ Shellane Mulcahy

 
			
	Name:	 	Shellane Mulcahy
	Title:	 	Authorized Signatory

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the Parties have executed this Fifth Amended and Restated
Investors’ Rights Agreement as of the day and year first above written. 
  

			
	ROCK SPRINGS CAPITAL MASTER FUND LP
	By:	 	Rock Springs General Partner LLC, its general partner
		
	By:	 	/s/ Mark Bussard
		 	Mark Bussard
		 	Member

  

			
	FOUR PINES MASTER FUND LP
	By:	 	Four Pines General Partner LLC, its general partner
		
	By:	 	/s/ Mark Bussard
		 	Mark Bussard
		 	Member

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	MEDICXI GROWTH CO-INVEST I LP
	By:	 	its manager Medicxi Ventures Management (Jersey) Limited
	
	/s/ Andrew Jeanne    
	Director

  

			
	MEDICXI GROWTH I LP
	By:	 	its manager Medicxi Ventures Management (Jersey) Limited
	
	/s/ Andrew Jeanne    
	Director

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	LUNDBECKFOND INVEST A/S
		
	By:	 	/s/ Mette Kirstine Agger

 
			
	Name:	 	Mette Kirstine Agger
	Title:	 	Managing Partner,
		 	Lundbeckfonden Ventures

 
			
		
	By:	 	/s/ Lene Skole

 
			
	Name:	 	Lene Skole
	Title:	 	Chief Executive Officer,
		 	Lundbeckfonden Invest A/S

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	ARIX BIOSCIENCE HOLDINGS LIMITED
		
	By:	 	/s/ Robert Lyne

 
			
	Name:	 	Robert Lyne
	Title:	 	Director

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

					
	INVESTORS:	  		  	
			
	ADVENT LIFE SCIENCES LLP	  		  	ADVENT LIFE SCIENCES FUND III LP
			
	By: /s/ Kaasim Mahmood                        	  		  	By: Advent Life Science LLP, its manager
			
	Name: Kaasim Mahmood	  		  	By: /s/ Kaasim Mahmood                        
			
	Title: General Partner	  		  	Name: Kaasim Mahmood
			
	 ADVENT LIFE SCIENCES FUND I LP
	  		  	Title: General Partner
			
	By: Advent Life Science LLP, its manager	  		  	ADVENT-HARRINGTON IMPACT FUND LP
			
	By: /s/ Kaasim Mahmood                        	  		  	By: Advent Life Science LLP, its manager
			
	Name: Kaasim Mahmood	  		  	By: /s/ Kaasim Mahmood                        
			
	Title: General Partner	  		  	Name: Kaasim Mahmood
			
	 ALS III CARRY AND CO-INVEST LP
	  		  	Title: General Partner
			
	By: Advent Life Science LLP, its manager	  		  	
			
	By: /s/ Kaasim Mahmood                        	  		  	
			
	Name: Kaasim Mahmood	  		  	
			
	Title: General Partner	  		  	

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	YSIOS BIOFUND II INNVIERTE, F.C.R.
		
	By:	 	YSIOS CAPITAL PARTNERS S.G.E.I.C.,
		 	S.A., its manager
		
	By:	 	/s/ Joes Jean Mairet

 
			
	Name:	 	Joel Jean Mairet
	Title:	 	Attorney-in-fact

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	CHIESI VENTURES, LP
	By: Chiesi Ventures, Inc., its General Partner
	By: Pappas Capital, LLC, its Management Company
		
	By:	 	/s/ Arthur M. Pappas
	Name: Arthur M. Pappas
	Title: CEO & Managing Partner

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	BELINDA A. TERMEER
		
	By:	 	/s/ Belinda A. Termeer

 
			
	Name:	 	Belinda A. Termeer

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	COLUMBUS INNVIERTE LIFE SCIENCE F.C.R.
		
	By:	 	/s/ Javier Garcia
	Name:	 	Javier Garcia
	Title:	 	General Partner

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	GARCIA-ATANCE LAFUENTE SALVADOR.
		
	By:	 	/s/ Salvador Garcia-Atance

 
			
	Name:	 	Salvador Garcia-Atance
	Title:	 	

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	MERCURY CAPITAL, S.L.
		
	By:	 	/s/ Nicolas Ayuso

 
			
	Name:	 	Nicolas Ayuso
	Title:	 	CEO

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	JV RISK TECHNOLOGIES, S.L.
		
	By:	 	/s/ Antonio Vila Casa

 
			
	Name:	 	Antonio Vila Casa
	Title:	 	Administrador Solidario

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	ALEXANDRIA VENTURE INVESTMENTS, LLC
	a Delaware limited liability company
		
	By:	 	 ALEXANDRIA REAL ESTATE
 EQUITIES, INC.,

a Maryland corporation, managing member

		
	By:	 	/s/ Aaron Jacobson

 
			
	Name:	 	Aaron Jacobson

 
			
	Title:	 	VP – Corporate Counsel

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ William W. Biggs

 
			
	Name:	 	William W. Biggs

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Gregory L. Biggs

 
			
	Name:	 	Gregory L. Biggs

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	ADAGE CAPITAL PARTNERS, LP
	By: Adage Capital Partners, GP, LLC, it’s General Partner
		
	By:	 	/s/ Dan Lehan

 
			
	Name:	 	Dan Lehan

 
			
	Title:	 	Chief Operating Officer

  
 Schedule A 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Roy Dunbar

 
			
	Name:	 	Roy Dunbar

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	 /s/ Lewis J. Green

			
	Name:	 	 Lewis J. Green 

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ John Maraganore

 
			
	Name:	 	John Maraganore

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Diana Frazier

 
			
	Name:	 	Diana Frazier

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Gregory T. Winner 

 
			
	Name:	 	Gregory T. Winner

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Robert Chew 

 
			
	Name:	 	Robert Chew

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	VELOCITY CAPITAL MANAGEMENT LLC
		
	By:	 	/s/ David Johnson 

 
			
	Name:	 	David Johnson 

 
			
	Title:	 	Partner

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Robert S. Milligan 

 
			
	Name:	 	Robert S. Milligan

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Robert Carpenter

 
			
	Name:	 	Robert Carpenter

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Israel Ruiz

 
			
	Name:	 	Israel Ruiz

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
		
	By:	 	/s/ Alan D. Solomont

 
			
	Name:	 	Alan D. Solomont

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	JUDY C. SWANSON REVOCABLE TRUST
		
	By:	 	/s/ Judy C. Swanson

 
			
	Name:	 	 Judy C. Swanson

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	AMY M. WINSLOW 2011 REVOCABLE TRUST

 
			
		
	By:	 	/s/ Amy M. Winslow

 
			
	Name:	 	Amy M. Winslow

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:

 
			
		
	By:	 	/s/ Alan E. Walts

 
			
	Name:	 	Alan E. Walts

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	EDWARD C. WINSLOW 2011 REVOCABLE TRUST

 
			
		
	By:	 	/s/ Edward C. Winslow

 
			
	Name:	 	Edward C. Winslow

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:

 
			
		
	By:	 	/s/ Edwina Wright

 
			
	Name:	 	Edwina Wright

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	MYELIN LP
	By: Myelin Management LLC, Inc., its General Partner

 
			
		
	 By:
	 	/s/ Matías Nisenson

 
			
	Name:	 	Matías Nisenson
	Title:	 	Manager

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:
	
	PAGS GROUP, LLC

 
			
		
	By:	 	/s/ Judy M. Pagliuca

 
			
	Name:	 	Judy M. Pagliuca
	Title:	 	Manager

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	INVESTORS:

 
			
		
	By:	 	/s/ Peter Elliot, PH.D.

 
			
	Name:	 	Peter Elliot, PH.D.

  
 Signature Page to
Fifth Amended and Restated Investors’ Rights Agreement 

 SCHEDULE A 

Schedule of Investors 

Salvador Garcia-Atance 

ADVENT LIFE SCIENCES LLP 

ADVENT LIFE SCIENCES FUND I LP 

ADVENT LIFE SCIENCES FUND III LP 

ADVENT-HARRINGTON IMPACT FUND LP 

ALS III CARRY AND CO-INVEST LP 

ALEXANDRIA VENTURE INVESTMENTS, LLC 

JOSE RAMON ARCE 
 ARIX
BIOSCIENCE HOLDINGS LIMITED 
 LAWRENCE C. BEST 

GREGORY L. BIGGS 

WILLIAM W. BIGGS 

  
 Schedule A 

 JESUS CAINZOS 

DR. JOSE CARLOS MONTILLA CANIS 

ROBERT CARPENTER 

ROBERT CHEW 
 CHIESI
VENTURES, LP 
 CARLOS GARCIA COGORRO 

COLUMBUS INNVIERTE LIFE SCIENCE F.C.R. 

ELISABET DE LOS PINOS REVOCABLE TRUST u/d/t dated 04-08-2016

 MATHIAS DÖPFNER 

DROIA S.A. 
 ROY DUNBAR

 ELICTA LLC 

  
 Schedule A 

 PETER ELLIOTT, PH.D. 

PETER B. FINN 
 DIANA
FRAZIER 
 ANTONIO GALINDEZ 

JAVIER GARCIA 
 MARIA
GARIN 
 LEWIS J. GEFFEN 

PEDRO P. GRANADILLO 

ANDREW AND EILEEN HOLTVEDT 

JAZZYA INVESTMENTS, S.L. 

JV RISK TECHNOLOGIES S.L. 

LANDA, LLC 
 LI-COR OF LINCOLN LLC 
 LUNDBECKFOND INVEST A/S 

  
 Schedule A 

 JOHN MARAGANORE 

MEILI TRUST DTD JULY 13, 2017 

MERCURY CAPITAL, S.L. 

ROBERT S. MILLIGAN 

LAURA B. MORSE 
 EDMUNDO
MUNIZ 
 CAROL NULMAN 

THE CAROL NULMAN TRUST DTD 10/3/2003 

PAGS GROUP, LLC 
 THE
RICHARD H. PETERS TRUST OF 2004 
 DR. RICHARD PILNIK 

MICHAEL DENNIS PRICE 

CARLOS ROBLES 
 PABLO
RODRIGUEZ 

  
 Schedule A 

 ISRAEL RUIZ 

EDUARDO SANCHIZ 

EDUARDO SANCHIZ & MARIA GARIN SANCHIZ 

PAOLA MARRI MALACRIDA SANTINI 

ALAN D. SOLOMONT 

MICHAEL A. STELLER 401(k), OPPENHEIMER 

JUDY C. SWANSON REVOCABLE TRUST 

BELINDA A. TERMEER 
 UBS
F/B/O TRAD. IRA (GREGORY T. WINNER) 
 GREGORY T. WINNER 

ALAN E. WALTS 
 AMY M.
WINSLOW 2011 REVOCABLE TRUST 
 EDWARD C. WINSLOW 2011 REVOCABLE TRUST 

  
 Schedule A 

 EDWINA WRIGHT 

MICHAEL S. WYZGA REVOCABLE TRUST 

YSIOS BIOFUND II INNVIERTE, F.C.R. 

MEDICXI GROWTH I LP and MEDICXI GROWTH CO-INVEST I LP 

Medicxi Ventures Management (Jersey) Limited 

Matrix Capital Management Master Fund, LP 

Velosity Capital Management LLC 

Citadel Multi-Strategy Equities Master Fund Ltd. 

Adage Capital 
 Rock
Springs Capital Master Fund LP 
 Four Pines Master Fund LP 

  
 Schedule AEX-10.1

 Exhibit 10.1 

AURA BIOSCIENCES, INC. 

AMENDED AND RESTATED 

2009 STOCK OPTION AND RESTRICTED STOCK PLAN 
  

	 	1.	 Purpose. 

Effective January 15, 2009, the Directors of Aura Biosciences, Inc. (the “Corporation”) adopted the “Aura Biosciences 2009
Long-Term Incentive Stock Option Plan” (“ Original Plan”). The Original Plan was approved by the stockholders of the Corporation on January 16, 2009. In accordance with Article 10 of the Original Plan, the Directors hereby amend
the Original Plan in certain respects, and restate the Original Plan, as so amended, in its entirety, as herein set forth (the Original Plan, as so amended and restated, the “ Plan”). 

The purpose of the Plan is to secure for and its shareholders the benefits arising from capital stock ownership by employees, officers and
directors of, and consultants or advisors to, the Corporation who are expected to contribute to the Corporation’s future growth and success. Except where the context otherwise requires, the term “Corporation” shall include all future
subsidiaries of the Corporation as defined in Section 424(£) of the Internal Revenue Code of 1986, as amended or replaced from time to time (the “Code”). Those provisions of the Plan which make express reference to
Section 422 shall apply only to Incentive Stock Options (as that term is defined in the Plan). 
 This Plan is intended to be a written
compensatory benefit plan within the meaning of Rule 701 of the federal Securities Act of 1933, as amended, and is intended to qualify under similar provisions of applicable State Blue Sky laws. 

 

	 	2.	 Type of Options, Restricted Stock Grants. and Administration. 

(a) Types of Options. Options granted pursuant to the Plan shall be authorized by action of the Administrator (as defined below) and may
be either incentive stock options (“Incentive Stock Options”) meeting the requirements of Section 422 of the Code or non-statutory options which are not intended to meet the requirements of Section 422 of the Code. 

(b) Restricted Stock. Shares of the Corporation’s $0.01 par value common stock (“Common Stock”) issued pursuant to the
Plan and subject to restrictions as the Administrator shall determine (“Restricted Stock”). 
 (c) Administration. The Plan
will be administered by the Administrator, whose construction and interpretation of the terms and provisions of the Plan shall be final and conclusive. The Administrator may, in its sole discretion, (i) grant options to purchase shares Common
Stock and issue shares upon exercise of such options as provided in the Plan and (ii) issue Restricted Stock. The Administrator shall have authority, subject to the express provisions of the Plan, to determine the optionees; to set exercise
prices, the number of shares subject to each option grant, and the vesting or other schedule by which any option may be exercisable; to construe, amend, and 

  
 1 

 
terminate the respective option agreements; to determine the terms and provisions of the respective option agreements, which need not be identical; to determine, subject to Section 3 hereof.
the persons who will be issued Restricted Stock pursuant to the Plan. the price to be paid for any such shares, the method of payment for such shares. and the restrictions to which such shares will be subject; to construe and interpret the Plan; to
prescribe. amend and rescind rules and regulations relating to the Plan; and to make all other determinations in the judgment of the Administrator necessary or desirable for the administration of the Plan and the agreements entered into pursuant to
the Plan. The Administrator may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any option agreement in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the
sole and final judge of such expediency. No director or person acting pursuant to authority delegated by the Administrator shall be liable for any action or determination under the Plan made in good faith. To the extent permitted by applicable law,
the Administrator may delegate any or all of its powers under the Plan to the Compensation Committee (the “Committee”). If and when the Common Stock is registered under the Securities Exchange Act of 1934 (the “Exchange Act”) the
Administrator shall appoint one such Committee of two members, each member of which shall be an “outside director” within the meaning of Section 162(m) of the Code and a “non-employee
director” as defined in Rule 16b-3 promulgated under the Exchange Act). All references in the Plan to the term “ Administrator “ shall mean either the Corporation’s Board of Directors or
the Compensation Committee thereof, to the extent the Compensation Committee is at the time responsible for the administration of the Plan). 
  

	 	3.	 Eligibility. 

Shares of Restricted Stock may be issued, and Options may be granted, to persons who are, at the time of issuance or grant, employees, officers
or directors of, or consultants or advisors to, the Corporation, or any subsidiary; provided, that the class of employees to whom Incentive Stock Options may be granted shall be limited to all employees of the Corporation, or any subsidiary.
A person who has been granted an option may, if he or she is otherwise eligible, be granted additional options if the Administrator shall so determine. 
  

	 	4.	 Stock Subject to Plan. 

Subject to adjustment as provided in Section 15 below, the maximum number of shares of Common Stock of the Corporation which may be issued
and sold under the Plan is Seven Hundred Twenty-Six Thousand Three Hundred Thirty-Four (726,334) shares. If an option granted under the Plan shall expire or terminate for any reason without having been
exercised in full, the unpurchased shares subject to such option shall again be available for subsequent option grants under the Plan. If shares issued upon exercise of an option under the Plan are tendered to the Corporation in payment of the
exercise price of an option granted under the Plan, such tendered shares shall again be available for subsequent option grants under the Plan; provided, that in no event shall such shares be made available pursuant to exercise of Incentive Stock
Options. 

  
 2 

	 	5.	 Forms of Option Agreements; Restricted Stock. 

As a condition to any grant under the Plan, each recipient shall execute: (a) an option or Restricted Stock agreement (as the case may be)
in such form not inconsistent with the Plan as may be approved by the Administrator and (b) a joinder agreement and limited power of attorney, each in forms attached to a stockholders agreement if applicable. 

 

	 	6.	 Purchase Price. 

(a) General. The purchase price per share of Common Stock deliverable upon the exercise an option shall be determined by the
Administrator, provided, however, that the exercise price shall not be less than 100% of the fair value of such stock, as determined by the Administrator, at the time of grant of such option, or less than 110% of such fair market value in the
case of options described in Section 11(b). The purchase price per share of Restricted Stock to be issued to a recipient hereunder shall be determined by the Administrator. 

(b) Payment of Purchase Price. Options granted under the Plan may provide for the payment of the exercise price by (i) delivery of
cash or a check to the order of the Corporation in an amount equal to the exercise price of such options, or, to the extent provided in the applicable option agreement, (ii) by delivery to the Corporation of shares of Common Stock of the
Corporation already owned by the optionee having a fair market value equal in amount to the exercise price of the options being exercised, (iii) by any other means which the Administrator determines are consistent with the purpose of the Plan
and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 and Regulation T promulgated by the Federal Reserve Board) or (iv) by any combination of such methods
of payment. The fair market value of any shares of the Corporation’s Common Stock or other non-cash consideration which may be delivered upon exercise of an option or which may be delivered pursuant to a
Restricted Stock agreement shall be determined by the Administrator. 
  

	 	7.	 Option Period. 

Each option and all rights thereunder shall expire on such date as shall be set forth in the applicable option agreement, except that, in the
case of an Incentive Stock Option, such date shall not be later than ten years after the date on which the option is granted and, in all cases, options shall be subject to earlier termination as provided in the Plan. 

 

	 	8.	 Exercise of Options. 

Each option granted under the Plan shall be exercisable either in full or in installments at such time or times and during such period as shall
be set forth in the agreement evidencing such option, subject to the provisions of the Plan. 
  

	 	9.	 Nontransferability of Options. 

Except as the Administrator may otherwise determine or provide in the applicable option agreement, options shall not be assignable or
transferable by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the optionee, shall be exercisable only by the optionee; provided,
however, that non-statutory options may be transferred pursuant to a qualified domestic relations order (as defined in Code Section 414(p)). 

  
 3 

	 	10.	 Effect of Termination of Employment or Other Relationship. 

Subject to the provisions of the Plan, the Administrator shall determine the period of time during which an optionee may exercise an option
following (i) the termination of the optionee’s employment or other relationship with the Corporation, or any subsidiary, or (ii) the death or disability of the optionee. Such periods shall be set forth in the agreement evidencing
such option. For the purposes of the Plan, employment shall not be deemed to be terminated solely because an optionee is transferred from the Corporation to any subsidiary thereof or to an acquiring or succeeding corporation (or an affiliate
thereof). 
  

	 	11.	 Incentive Stock Options. 

Options granted under the Plan which are intended to be Incentive Stock Options shall be subject to the following additional terms and
conditions: 
 (a) Express Designation. All Incentive Stock Options granted under the Plan shall, at the time of grant, be
specifically designated as such in the option agreement covering such Incentive Stock Options. 
 (b) 10% Shareholder. If any
employee to whom an Incentive Stock Option is to be granted under the Plan is, at the time of the grant of such option, the owner of stock possessing more than 10% of the total combined voting power of all classes of stock of the Corporation (after
taking into account the attribution of stock ownership rules of Section 424(d) of the Code), then the following special provisions shall be applicable to the Incentive Stock Option granted to such individual: 

(i) the purchase price per share of the Common Stock subject to such Incentive Stock Option shall not be less than 110% of the
fair market value of one share of Common Stock at the time of grant; and 
 (ii) the option exercise period shall not exceed
five years from the date of grant. 
 (c) Dollar Limitation. For so long as the Code shall so provide, options granted to any
employee under the Plan (and any other incentive stock option plans of the Corporation) which are intended to constitute Incentive Stock Options shall not constitute Incentive Stock Options to the extent that such options, in the aggregate, become
exercisable for the first time in any one calendar year for shares of Common Stock with an aggregate fair market value (determined as of the respective date or dates of grant) of more than $100,000. 

  
 4 

 (d) Termination of Employment, Death or Disability. No Incentive Stock Option may be
exercised unless, at the time of such exercise, the optionee is, and has been continuously since the date of grant of his or her option, employed by the Corporation, or any subsidiary, except that: 

(i) an Incentive Stock Option may be exercised within the period of three months after the date the optionee ceases to be an
employee of the Corporation, or any subsidiary (or within such lesser period as may be specified in the applicable option agreement); provided, that the agreement with respect to such option may designate a longer exercise period and that any
exercise after such three-month period shall be treated as the exercise of a non-statutory option under the Plan; 

(ii) if the optionee dies while in the employ of the Corporation, or any subsidiary, or within three months after the optionee
ceases to be such an employee, the Incentive Stock Option may be exercised by the person to whom it is transferred by will or the laws of descent and distribution within the period of one year after the date of death (or within such lesser period as
may be specified in the applicable option agreement); and 
 (iii) if the optionee becomes disabled (within the meaning of
Section 22(e)(3) of the Code or any successor provision thereto) while in the employ of the Corporation, or any subsidiary, the Incentive Stock Option may be exercised within the period of one year after the date the optionee ceases to be such
an employee because of such disability (or within such lesser period as may be specified in the applicable option agreement). 
 For all
purposes of the Plan and any option granted hereunder, “employment” shall be defined in accordance with the provisions of Section l.421-7(h) of the Income Tax Regulations (or any successor
regulations) and shall include employment by the Corporation, or any subsidiary. Employment shall not be deemed to be terminated because an optionee is transferred from one of the Corporation, or any subsidiary to another one of the Corporation, or
any subsidiary. Notwithstanding the foregoing provisions, no Incentive Stock Option may be exercised after its expiration date. 
  

	 	12.	 Additional Provisions. 

(a) Additional Option Provisions. The Administrator may, in its sole discretion, include additional provisions in option agreements
covering options granted under the Plan, including, without limitation, restrictions on transfer, repurchase rights, commitments to pay cash bonuses, to make, arrange for or guaranty loans or to transfer other property to optionees upon exercise of
options, or such other provisions as shall be determined by the Administrator; provided that such additional provisions shall not be inconsistent with any other term or condition of the Plan and such additional provisions shall not cause any
Incentive Stock Option granted under the Plan to fail to qualify as an Incentive Stock Option within the meaning of Section 422 of the Code. 

  
 5 

 (b) Acceleration, Extension, Etc. The Administrator may, in its sole discretion,
(i) accelerate the date or dates on which all or any particular option or options granted under the Plan may be exercised or (ii) extend the dates during which all, or any particular, option or options granted under the Plan may be
exercised; provided, however, that no such extension shall be permitted if it would cause the Plan to fail to comply with Section 422 of the Code. 
  

	 	13.	 General Restrictions. 

(a) Investment Representations. The Corporation may require any person to whom an option is granted, or any shares of Restricted Stock
are being issued, as a condition of exercising such option or acquiring such shares, to give written assurances in substance and form satisfactory to the Corporation to the effect that such person is acquiring the Common Stock for his or her own
account for investment and not with any present intention of selling or otherwise distributing the same, and to such other effects as the Corporation deems necessary or appropriate in order to comply with federal and applicable state securities
laws, or with covenants or representations made by the Corporation in connection with any public offering of its Common Stock. 
 (b)
Compliance With Securities Laws. Each option shall be subject to the requirement that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject to such option upon any
securities exchange or under any state or federal law, or the consent or approval of any governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other
condition is necessary as a condition of, or in connection with, the issuance or purchase of shares thereunder, such option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, or
satisfaction of such condition shall have been effected or obtained on conditions acceptable to the Administrator. Nothing herein shall be deemed to require the Corporation to apply for or to obtain such listing, registration or qualification, or to
satisfy such condition. 
  

	 	14.	 Rights as a Shareholder. 

The holder of an option shall have no rights as a shareholder with respect to any shares covered by the option (including, without limitation,
any rights to receive dividends or non-cash distributions with respect to such shares) until the date of issue of a stock certificate to him or her for such shares. No adjustment shall be made for
dividends or other rights for which the record date is prior to the date such stock certificate is issued. 
  

	 	15.	 Adjustment Provisions for Recapitalizations and Related Transactions. 

(a) General. If, through or as a result of any merger, consolidation, sale of all or substantially all of the assets of the Corporation,
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction, 

(i) the outstanding shares of Common Stock are increased, decreased or exchanged for a different number or kind of shares or
other securities of the Corporation, or 
 (ii) additional shares or new or different shares or other securities of the
Corporation or other non-cash assets are distributed with respect to such shares of Common Stock or other securities, 

  
 6 

 an appropriate and proportionate adjustment shall be made in (x) the maximum number and kind of shares
reserved for issuance under the Plan, (y) the number and kind of shares or other securities subject to any then outstanding options under the Plan, and (z) the price for each share subject to any then outstanding options under the Plan,
without changing the aggregate purchase price as to which such options remain exercisable. Notwithstanding the foregoing, no adjustment shall be made pursuant to this Section 15 if such adjustment would cause the Plan to fail to comply with
Section 422 of the Code. If this Section 15 applies and Section 16 also applies to any event, then Section 16 shall be applicable to such event and this Section 15 shall not be applicable. 

(b) Administrator Authority to Make Adjustments. Any adjustments under this Section 15 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued under the Plan on account of any such adjustments. 

 

	 	16.	 Merger. Consolidation, Asset Sale, Liquidation, etc. 

(a) General. Subject to Section 16(b), if an Acquisition Event (as defined below) is expected to occur, (A) all then unvested
Outstanding Options (which term shall include all vested and unvested, but unexercised Options specified in all issued, outstanding and then currently binding Stock Option Agreements) shall terminate immediately prior to the consummation of such
Acquisition Event, and (B) the Administrator shall take any one or more or none of the following actions with respect to all then vested Outstanding Options: 

(i) provide that such vested Outstanding Options shall be assumed, or equivalent options shall be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof), provided that any such options substituted for Outstanding Incentive Stock Options shall meet the requirements of Section 424(a) of the Code; 

(ii) upon written notice to the optionees, provide that all then vested Outstanding Options will terminate immediately prior to
the consummation of such Acquisition Event, except to the extent exercised by the optionees before the consummation of such Acquisition Event; 

(iii) in the event of a merger under the terms of which holders of the Common Stock of the Corporation will receive upon
consummation thereof a cash or stock payment for each share surrendered in the merger (the “Merger Price” ), make or provide for a cash or stock payment to each optionee equal to (A) the Merger Price times the number of shares of
Common Stock issuable to that Optionee upon the exercise by that Optionee of such of that Optionee’s vested Outstanding Options (whether or not then exercisable at prices not in excess of the Merger Price) which that Optionee actually elects to
exercise, less (B) the aggregate exercise price of all such Outstanding Options which the Optionee actually exercises in exchange for the termination of all of that Optionee’s Outstanding Options; 

(iv) terminate each such vested Outstanding Option in exchange for a cash payment equal to the amount by which the value of the
Common Stock issuable upon exercise of such Outstanding Option exceeds the exercise price with respect to such Common Stock; or 

  
 7 

 (v) provide for a combination of any one or more of the foregoing options or
any other plan which would be equitable, in the good faith judgment of the Administrator, to the holders of vested Outstanding Options. 
 An
“Acquisition Event” shall mean: (A) any merger or consolidation which results in the voting securities of the Corporation outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by
being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power of the voting securities of the Corporation or such surviving or acquiring entity outstanding immediately after such merger or
consolidation, (B) any sale of all or substantially all of the assets of the Corporation, or (C) the complete liquidation of the Corporation. 

(b) Substitute Options. The Corporation may grant options under the Plan in substitution for options held by employees of another
corporation who become employees of the Corporation, or a subsidiary of the Corporation, as the result of a merger or consolidation of the employing corporation with the Corporation or a subsidiary of the Corporation, or as a result of the
acquisition by the Corporation, or one of its subsidiaries, of property or stock of the employing corporation. The Corporation may direct that substitute options be granted on such terms and conditions as the Administrator considers appropriate in
the circumstances. 
  

	 	17.	 No Special Employment Rights. 

Nothing contained in the Plan or in any option shall confer upon any optionee any right with respect to the continuation of his or her
employment by the Corporation or interfere in any way with the right of the Corporation at any time to terminate such employment or to increase or decrease the compensation of the optionee. 

 

	 	18.	 Other Employee Benefits. 

Except as to plans which by their terms include such amounts as compensation, the amount of any compensation deemed to be received by an
employee as a result of the exercise of an option or the sale of shares received upon such exercise will not constitute compensation with respect to which any other employee benefits of such employee are determined, including, without limitation,
benefits under any bonus, pension, profit-sharing, life insurance or salary continuation plan, except as otherwise specifically determined by the Administrator. 
  

	 	19.	 Amendment of the Plan. 

(a) The Administrator may at any time, and from time to time, modify or amend the Plan in any respect, except that if at any time the approval
of the shareholders of the Corporation is required under Section 422 of the Code or any successor provision with respect to Incentive Stock Options, the approval of the shareholders shall be required to ratify such modification or amendment.
Amendments shall become effective as described in Section 22(a). 

  
 8 

 (b) The termination or any modification or amendment of the Plan shall not, without the
consent of an optionee, affect his or her rights under an option previously granted to him or her. With the consent of the optionee affected, the Administrator may amend outstanding option agreements in a manner not inconsistent with the Plan. The
Administrator shall have the right to amend or modify the terms and provisions of the Plan and of any outstanding Incentive Stock Options granted under the Plan to the extent necessary to qualify any or all such options for such favorable federal
income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section 422 of the Code. 
  

	 	20.	 Withholding. 

The Corporation shall have the right to deduct from payments of any kind otherwise due to the optionee any federal, state or local taxes of any
kind required by law to be withheld with respect to any shares issued upon exercise of options under the Plan, or any Restricted Stock issued under the Plan. Subject to the prior approval of the Corporation, which may be withheld by the Corporation
in its sole discretion, the optionee may elect to satisfy such obligations, in whole or in part, 
 (i) by causing the
Corporation to withhold shares of Common Stock otherwise issuable pursuant to the exercise of an option, or 
 (ii) by
delivering to the Corporation shares of Common Stock already owned by the optionee. The shares so delivered or withheld shall have a fair market value equal to such withholding obligation. The fair market value of the shares used to satisfy such
withholding obligation shall be determined by the Corporation as of the date that the amount of tax to be withheld is to be determined. An optionee who has made an election pursuant to this Section 20(a) may only satisfy his or her withholding
obligation with shares of Common Stock which are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. 
  

	 	21.	 Cancellation and New Grant of Options. Etc. 

The Administrator or the Directors shall have the authority to effect, at any time and from time to time, with the consent of the affected
optionees, 
 (i) the cancellation of any or all outstanding options under the Plan and the grant in substitution therefor of
new options under the Plan covering the same or different numbers of shares of Common Stock and having an option exercise price per share which may be lower or higher than the exercise price per share of the cancelled options, or 

(ii) the amendment of the terms of any and all outstanding options under the Plan to provide an option exercise price per share
which is higher or lower than the then current exercise price per share of such outstanding options. 
  

	 	22.	 Effective Date and Duration of the Plan. 

(a) Effective Date. The Plan is intended to be effective retroactive to January 15, 2009, to the extent not inconsistent with
applicable law or with the terms of any Award (as defined in the Original Plan) outstanding on the date of adoption of this (amended and restated) Plan, the amendment of which would require the written consent of the holder of the Award. Amendments
to the Plan not requiring shareholder approval shall become effective when 

  
 9 

 
adopted by the Administrator or as otherwise specified by the Administrator or set forth in the instrument of amendment. Amendments to the Plan requiring shareholder approval (as provided in
Section 19) shall become effective when so approved, retroactive to the date of adoption by the Administrator. No Incentive Stock Option granted after the date of such amendment shall become exercisable (to the extent that such amendment to the
Plan was required to enable the Corporation to grant such Incentive Stock Option to a particular optionee) unless and until such amendment shall have been approved by the Corporation’s shareholders, and if such shareholder approval is not
obtained within twelve months of the Administrator’s adoption of such amendment, any Incentive Stock Options granted on or after the date of such amendment shall terminate to the extent that such amendment to the Plan was required to enable the
Corporation to grant such option to a particular optionee. Subject to this limitation, options may be granted under the Plan at any time after the effective date and before the date fixed for termination of the Plan. 

(b) Termination. Unless sooner terminated in accordance with Section 16, the Plan shall terminate, with respect to Incentive Stock
Options, upon the earlier of the following events: 
 (i) the close of business on the day next preceding the tenth
anniversary of the date of its adoption by the Administrator, or 
 (ii) the date on which all shares available for issuance
under the Plan shall have been issued pursuant to the exercise or cancellation of options granted under the Plan. 
 If the date of termination is
determined under (i) above, then options outstanding on such date shall continue to have force ·and effect in accordance with the provisions of the instruments evidencing such options. 

Unless sooner terminated in accordance with Section 16, the Plan shall terminate with respect to options which are not Incentive Stock
Options on the date specified in (ii) above. 
  

	 	23.	 Provision for Foreign Participants. 

The Administrator may, without amending the Plan, modify awards or options granted to participants who are foreign nationals or employed
outside the United States to recognize differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. 

 

			
	AURA BIOSCIENCES, INC.
		
	By:	 	/s/ Elisabet de los Pinos
		 	Elisabet de los Pinos, Ph.D.
		 	Chief Executive Officer and President

  
 10 

 AURA BIOSCIENCES, INC.  

INCENTIVE STOCK OPTION AGREEMENT 

1. Grant of Option. Effective as of [•] (“Date of Grant”), AURA BIOSCIENCES, INC., a Delaware corporation (the
“Corporation”), hereby grants to [NAME] (the “Optionee”), an option, pursuant to the Corporation’s 2009 Amended and Restated Stock Option and Restricted Stock Plan, as further amended, (the “Plan”), to purchase an
aggregate of [•] shares of the Corporation’s $0.00001 par value common stock (“Common Stock”) at a price of [•] per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan.
Except where the context otherwise requires, the term “Corporation” shall include all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or replaced
from time to time (the “Code”). 
 2. Incentive Stock Option. This option is intended to qualify as an incentive stock
option (“Incentive Stock Option”) within the meaning of Section 422 of the Code. 
 3. Exercise of Option and Provisions
for Termination. 
 (a) Vesting Schedule. Except as otherwise provided in this Agreement, this option may be exercised prior to
the tenth (10th) anniversary of the Date of Grant (hereinafter the “Expiration Date”). 

This option shall vest as follows: [on [•], a total of [•] shares shall be deemed fully vested and thereafter, commencing as of
[•], an additional [•] shares shall vest monthly on the first (1st) day of each consecutive monthly anniversary during the term of the Optionee’s employment by the Corporation for
the next thirty-six (36) months so long as the Optionee is employed by the Corporation and in accordance with the terms of this Incentive Stock Option Agreement]. 

If the Optionee’s employment is terminated by the Corporation without Cause (as defined in Section 3(f)) within twelve
(12) months after a Sale Event (as defined in Section 3(g)), then all of the Optionee’s unvested options will accelerate and vest immediately. 

The right of exercise shall be cumulative so that if the option is not exercised to the maximum extent permissible during any exercise period,
it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not be exercised at any time on or after the Expiration
Date, except as otherwise provided in Section 3(e) below. 
 (b) Exercise Procedure. Subject to the conditions set forth in this
Agreement, this option shall be exercised by the Optionee’s delivery of a written notice of exercise in the form of attached hereto and marked as Exhibit 1 to the Treasurer of the Corporation, specifying the number of shares to be
purchased and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section 4, and a joinder agreement and limited power of attorney, each in form attached to that certain Stockholders Agreement defined in
the Plan. Such exercise shall be effective upon receipt by the Treasurer of the Corporation of such written notice together with the required payment and the said joinder agreement and limited power of attorney executed by the Optionee. The Optionee
may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. 

  
 1 

 (c) Continuous Employment Required. Except as otherwise provided in this
Section 3, this option may not be exercised unless the Optionee, at the time he or she exercises this option, is, and has been at all times since the Date of Grant of this option, an employee of the Corporation or any subsidiary. For all
purposes of this option, (i) “employment” shall be defined in accordance with the provisions of Section 1.421-7(h) of the Income Tax Regulations or any successor regulations and shall include
employment by the Corporation or any subsidiary, and (ii) if this option shall be assumed or a new option substituted therefor in a transaction to which Section 424(a) of the Code applies, employment by such assuming or substituting corporation
(hereinafter called the “Successor Corporation”) shall be considered for all purposes of this option to be employment by the Corporation. 

For all purposes under this Agreement, Optionee’s employment shall not be deemed to be terminated because Optionee’s employment is
transferred from one of the Corporation or any subsidiary to another one of the Corporation or any subsidiary. 
 (d) Exercise Period
Upon Termination of Employment. If the Optionee ceases to be employed by the Corporation or any subsidiary for any reason, then, except as provided in paragraphs (e) and (f) below, the right to exercise this option shall terminate three
(3) months after such cessation (but in no event after the Expiration Date), provided that this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The
Corporation’s obligation to deliver shares upon the exercise of this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements, arising by reason of this option
being treated as a non-statutory option or otherwise. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date, materially violates the
non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to
exercise this option shall terminate immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation. 

(e) Exercise Period Upon Death or Disability. If the Optionee dies or becomes disabled (within the meaning of Section 22(e)(3) of
the Code) prior to the Expiration Date while he or she is an employee of the Corporation or any subsidiary, or if the Optionee dies within three months after the Optionee ceases to be an employee of the Corporation or any subsidiary (other than as
the result of a discharge for “cause” as specified in paragraph (f) below), this option shall be exercisable within the period of one year following the date of death or disability of the Optionee (but in no event after the Expiration
Date), by the Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent this option was exercisable by the Optionee on the date of
his or her death or disability. Except as otherwise indicated by the context, the term “Optionee,” as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires the right to exercise this option
by bequest or inheritance or otherwise by reason of the death of the Optionee. 

  
 2 

 (f) Discharge for Cause. If the Optionee, prior to the Expiration Date, is discharged
by the Corporation or any subsidiary for Cause (as defined below), the right to exercise this option shall terminate immediately upon the Optionee being given notice of such cessation of employment whether the actual cessation of employment is
immediate or occurs at a later date. “Cause” shall mean (i) dishonest statements or acts by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation, or any of the Corporation’s current or
prospective customers, suppliers vendors or other third parties with which such entity does business; (ii) the Optionee’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;
(iii) failure to perform to the reasonable satisfaction of the Board of Directors of the Corporation (the “Board”) the Optionee’s duties and responsibilities assigned by the Board which failure continues, in the reasonable
judgment of the Board, after written notice given to the Optionee by the Board; (iv) gross negligence, willful misconduct or insubordination by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation; or
(v) a violation of any provision of any agreement(s) between the Optionee and the Corporation relating to noncompetition, nondisclosure and/or assignment of inventions. The Optionee shall be considered to have been discharged for Cause if the
Corporation or any subsidiary determines, within 30 days after the Optionee’s resignation, that discharge for Cause was warranted. In the event Optionee’s employment relationship with the Corporation is suspended pending investigation of
whether such relationship shall be terminated for Cause, all Optionee’s rights under this option, including the right to exercise this option, shall be suspended during the investigation period. 

(g) Sale Event. “Sale Event” means the consummation of (i) the dissolution or liquidation of the Corporation,
(ii) the sale of all or substantially all of the assets of the Corporation on a consolidated basis to an unrelated person or entity (a “Person”), (iii) a merger, reorganization or consolidation involving the Corporation in which the
shares of the Corporation’s voting equity outstanding immediately prior to such transaction represent or are converted into or exchanged for securities of the surviving or resulting entity immediately upon completion of such transaction which
represent less than fifty percent (50%) of the outstanding voting power of such surviving or resulting entity, (iv) the acquisition of all or a majority of the outstanding voting equity of the Corporation in a single transaction or a series of
related transactions by a Person or a group of Persons, or (v) any other acquisition of the business of the Corporation, as determined by the Board; provided, however, that the Corporation’s initial public offering, any subsequent public
offering or another capital raising event, or a merger effected solely to change the Corporation’s domicile shall not constitute a “Sale Event.” 

4. Payment of Purchase Price. 

(a) Method of Payment. Payment of the purchase price for shares purchased upon exercise of this option shall be made (i) by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii) subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii) by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 and Regulation T promulgated by the
Federal Reserve Board), or (iv) by any combination of such methods of payment. 

  
 3 

 (b) Valuation of Shares or Other Non-Cash
Consideration Tendered in Payment of Purchase Price. For the purposes hereof, the fair market value of any share of the Corporation’s Common Stock or other non-cash consideration which
may be delivered to the Corporation in exercise of this option shall be determined in good faith by the Administrator. 
 (c) Delivery of
Shares Tendered in Payment of Purchase Price. If the Optionee exercises options by delivery of shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock of the Corporation to be delivered
shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common Stock of the Corporation will not be
accepted in payment of the purchase price of shares acquired upon exercise of this option. 
 (d) Restrictions on Use of Option
Stock. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered were acquired within twelve
(12) months before the date of such tender through the exercise of an option granted under the Plan or any other stock option or restricted stock plan of the Corporation. 

5. Delivery of Shares; Compliance With Securities Laws, Etc. 

(a) General. The Corporation shall, upon payment of the option price for the number of shares purchased and paid for, make prompt
delivery of such shares to the Optionee, provided that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be extended
for the period necessary to complete such action. 
 (b) Listing, Qualification, Etc. This option shall be subject to the requirement
that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of any
governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase of
shares hereunder, this option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms
acceptable to the Administrator. Nothing herein shall be deemed to require the Corporation to apply for, effect or obtain such listing, registration, qualification, or disclosure, or to satisfy such other condition. 

6. Nontransferability of Option. Except as provided in paragraph (e) of Section 3, this option is personal and no rights
granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise), nor shall any such rights be subject to execution, attachment or similar process. Upon any attempt to transfer, assign,
pledge, hypothecate or otherwise dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of
the Corporation, become null and void. 

  
 4 

 7. No Special Employment Rights. Nothing contained in the Plan or this option shall
be construed or deemed by any person under any circumstances to bind the Corporation or any subsidiary to continue the employment of the Optionee for the period within which this option may be exercised. 

8. Rights as a Shareholder. The Optionee shall have no rights as a shareholder with respect to any shares which may be purchased by
exercise of this option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares) unless and until a certificate representing such shares is duly
issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. 

9. Adjustment Provisions. 

(a) General. In the event of a transaction described in Section 15(a) of the Plan, the Optionee shall, with respect to this option
or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Section 15(a) of the Plan. 

(b) Administrator Authority to Make Adjustments. Any adjustments under this Section 9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. 

(c) Limits on Adjustments. No adjustment shall be made under this Section 9 which would, within the meaning of any applicable
provision of the Code, constitute a modification, extension or renewal of this option or a grant of additional benefits to the Optionee. 

10. Mergers, Consolidation, Distributions, Liquidations Etc. In the event of a merger, consolidation, distribution, liquidation or
other similar event described in Section 16(a) of the Plan, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in
Section 16(a) of the Plan. 
 11. Withholding Taxes. The Corporation’s obligation to deliver shares upon the exercise of
this option shall be subject to the Optionee’s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. 

12. Limitations on Disposition of Incentive Stock Option Shares. It is understood and intended that this option shall qualify as an
“incentive stock option” as defined in Section 422 of the Code. Accordingly, the Optionee understands that in order to obtain the benefits of an incentive stock option under Section 422 of the Code, no sale or other disposition
may be made of any shares acquired upon exercise of the option within one year after the day of the transfer of such shares to the Optionee, nor within two years after the grant of the option. If the Optionee intends to dispose, or does dispose
(whether by sale, exchange, gift, transfer or otherwise), of any such shares within said periods, he or she will notify the Corporation in writing within ten days after such disposition. 

  
 5 

 13. Investment Representations; Legends. 

(a) Representations. The Optionee represents, warrants and covenants that: 

(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee’s account for investment only and
not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the “Securities Act”) or any rule or regulation under the Securities Act. 

(ii) The Optionee has had such opportunity as he or she has deemed adequate to obtain from representatives of the Corporation
such information as is necessary to permit the Optionee to evaluate the merits and risks of his or her investment in the Corporation. 

(iii) The Optionee is able to bear the economic risk of holding shares acquired pursuant to the exercise of this option for an
indefinite period. 
 (iv) The Optionee understands that (A) the shares acquired pursuant to the exercise of this option
will not be registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act; (B) such shares cannot be sold, transferred or otherwise disposed of unless they are subsequently
registered under the Securities Act or an exemption from registration is then available; (C) in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for at least two years and even then
will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public and other terms and conditions of Rule 144 are complied with; and (D) there is now no
registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to the exercise of this
option under the Securities Act. 
 (v) The Optionee agrees that, if the Corporation offers any of its Common Stock for sale
pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a) one hundred eighty (180) days following
the effective date of the relevant registration statement filed under the Securities Act in connection with the Corporation’s initial public offering of Registrable Securities, or (b) ninety (90) days following the effective date of the
relevant registration statement in connection with any other public offering of Registrable Securities; provided, however, that all officers and directors of the Corporation and all 1% or greater stockholders of the Corporation enter
into similar agreements. 
 By making payment upon exercise of this option, the Optionee shall be deemed to have reaffirmed, as of the date
of such payment, the representations made in this Section 13. 

  
 6 

 (b) Legends on Stock Certificates. All stock certificates representing shares of
Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state law: 

“The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 and may not be transferred,
sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel satisfactory to the
Corporation to the effect that registration under such Act is not required.” 
 “The shares of stock represented by this
certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the issuer.” 

14. Miscellaneous. 
 (a)
Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation and the Optionee. 

(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their respective addresses set
forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. 
 (c)
This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. 
 Signature Page Follows

  
 7 

 DATED effective as of the Date of Grant. 

 

									
		 		 	AURA BIOSCIENCES, INC.
					
	Date:	 		 		 	By:	 	 
		 		 		 	 Elisabet de los Pinos, Ph.D.

President and CEO
 Hereunto Duly Authorized

 OPTIONEE’S ACCEPTANCE 

The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation’s Amended and Restated 2009 Stock Option and Restricted Stock Plan, as further amended. 
  

					
		 		 	OPTIONEE:
			
	Date:	 		 	  

		 		 	[NAME]

  
 8 

 EXHIBIT 1 

Notice of Option Exercise 
 Date: 

TO: The Treasurer of AURA BIOSCIENCES, INC.: 

The undersigned, in accordance with the provisions of a Stock Option Agreement (“Agreement”) between AURA BIOSCIENCES, INC.
(“Corporation”) and the undersigned, hereby gives notice pursuant to Section 3(b) of the Agreement of the undersigned’s exercise of the option pursuant to the Agreement to purchase
(#)                    common shares of the Corporation for the aggregate payment for said shares of
$                    (“Price”) payable as follows (please check one): 

 

			
	☐    	  	by the tender of a check for immediately available funds for the entire Price (enclose check made payable to “AURA BIOSCIENCES, INC.”);
		
	☐	  	subject to the consent of the Corporation, by tendering (#)                    shares of the Corporation’s
(type)                    stock;
		
	☐	  	subject to the consent of the Corporation, by tendering $                    in cash (enclose check made payable to
“AURA BIOSCIENCES, INC.”) and (#) shares of the Corporation’s
(type)                                        
stock; or
		
	☐	  	by alternative means approved by the Corporation’s Administrator as follows:
		  	  

		  	  

		  	  

 The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section 13(a) of the Agreement are true and correct as of the date of this Notice. The undersigned hereby (a) agrees that the undersigned is acquiring Stock of the Corporation subject to the terms and conditions of
the Voting Agreement and ROFR Agreement; (b) agrees that the Stock acquired by the undersigned shall be bound by and subject to the terms of the Voting Agreement and ROFR Agreement; (c) adopts the Voting Agreement and ROFR Agreement with the
same force and effect as if the undersigned were originally a party thereto; (d) agrees that any notice required or permitted by the Voting Agreement or ROFR Agreement shall be given to the undersigned at the address listed below the
undersigned’s signature below; (e) agrees to be bound by (i) the Voting Agreement as a “Common Holder” thereunder and (ii) the ROFR Agreement as a “Key Holder” thereunder irrespective of whether the undersigned
will or will not hold one percent (1%) or more of the Corporation’s Stock (as defined in the ROFR Agreement); (f) agrees that a copy of this document may be used as a counterpart signature page or adoption agreement to each of the Voting
Agreement and the ROFR Agreement; and (g) agrees to execute and deliver to the Corporation additional or alternative adoption agreements (in forms acceptable to the Corporation) to each of the Voting Agreement and ROFR Agreement if so required
by the Corporation. 

  
 9 

 The undersigned represents and warrants to the Corporation that all of the representations
and warranties set forth in Section 13(a) of the Agreement are true and correct as of the date of this Notice. 
  

			
	Signature:	 	 

 
			
		
	Name:	 	 

 
			
		
	Address:	 	 

 
			
	
	Social Security Number:
	
	 

  
 10 

 AURA BIOSCIENCES, INC. 

NON-STATUTORY STOCK OPTION AGREEMENT 

1. Grant of Option. Effective [•] (“Date of Grant”), AURA BIOSCIENCES, INC., a Delaware corporation (the
“Corporation”), hereby grants to [NAME] (the “Optionee”) an option, pursuant to the Corporation’s Amended and Restated 2009 Stock Option and Restricted Stock Plan (the “Plan”), to purchase an aggregate of [•]
shares of the Corporation’s $0.00001 par value common stock (“Common Stock”) at a price of [•] per share, purchasable as set forth in and subject to the terms and conditions of this option and the Plan (the “Shares”).
Except where the context otherwise requires, the term “Corporation” shall include the all present and future subsidiaries of the Corporation as defined in Sections 424(e) and 424(f) of the Internal Revenue Code of 1986, as amended or
replaced from time to time (the “Code”). 
 2. Non-Statutory Stock
Option. This option is not intended to qualify as an incentive stock option within the meaning of Section 422 of the Code. 

3. Exercise of option and Provisions for
Termination. 
 (a) Vesting Schedule. Except as otherwise provided in this Agreement, this option may be exercised prior
to the tenth (10th) anniversary of the Date of Grant (hereinafter the “Expiration Date”). 
 This option shall vest as follows:
The Shares shall vest [equally on an annual basis with the first vesting occurring on [DATE] and thereafter, on the second and third anniversary dates]. 

The right of exercise shall be cumulative so that if the option is not exercised to the maximum extent permissible during any exercise period,
it shall be exercisable, in whole or in part, with respect to all shares not so purchased at any time prior to the Expiration Date or the earlier termination of this option. This option may not be exercised at any time on or after the Expiration
Date, except as otherwise provided in Section 3(e) below. 
 (b) Exercise Procedure. Subject to the conditions set forth in this
Agreement, this option shall be exercised by the Optionee’s delivery of a written notice of exercise in the form attached hereto and marked as Exhibit 1 to the Treasurer of the Corporation, specifying the number of shares to be purchased
and the purchase price to be paid therefor and accompanied by payment in full in accordance with Section 4. Such exercise shall be effective upon receipt by the Treasurer of the Corporation of such written notice together with the required
payment. The Optionee may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten (10) whole shares. 

(c) Continuous Relationship with the Corporation. Except as otherwise provided
in this Section 3, this option may not be exercised unless the Optionee, at the time it exercises this option, is, and has been at all times since the date of grant of this option, an employee, officer or director of, or consultant or advisor
to, the Corporation or any subsidiary (an “Eligible Optionee”). 

 (d) Exercise Period Upon Termination of Relationship with the Corporation. If the
Optionee ceases to be an Eligible Optionee for any reason, then, except as provided in paragraphs (e) and (f) below, the right to exercise this option shall terminate three (3) months after such cessation (but in no event after the
Expiration Date), provided that this option shall be exercisable only to the extent that the Optionee was entitled to exercise this option on the date of such cessation. The Corporation’s obligation to deliver shares upon the exercise of
this option shall be subject to the satisfaction of all applicable federal, state and local income and employment tax withholding requirements. Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date, materially violates the
noncompetition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Optionee and the Corporation or any subsidiary, the right to exercise this option shall terminate
immediately upon written notice to the Optionee from the Corporation or any subsidiary describing such violation. 
 (e) Exercise
Period Upon Death or Disability. If the Optionee dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Expiration Date while it is an
Eligible Optionee, or if the Optionee dies within three (3) months after the Optionee ceases to be an Eligible Optionee (other than as the result of a termination of such relationship by the Corporation or any subsidiary for “cause”
as specified in paragraph (t) below), this option shall be exercisable, within the period of one (1) year following the date of death or disability of the Optionee (whether or not such exercise occurs before the Expiration Date), by the
Optionee or by the person to whom this option is transferred by will or the laws of descent and distribution, provided that this option shall be exercisable only to the extent that this option was exercisable by the Optionee on the date of his death
or disability. Except as otherwise indicated by the context, the term “Optionee,” as used in this option, shall be deemed to include the estate of the Optionee or any person who acquires the right to exercise this option by bequest or
inheritance or otherwise by reason of the death of the Optionee. 
 (f) Discharge for Cause. If the Optionee, prior to the Expiration
Date, is discharged by the Corporation or any subsidiary for Cause (as defined below), the right to exercise this option shall terminate immediately upon such cessation of employment. “Cause” shall mean (i) dishonest statements or
acts by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation, or any of the Corporation’s current or prospective customers, suppliers vendors or other third parties with which such entity does business;
(ii) the Optionee’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform to the reasonable satisfaction of the Board of Directors of the
Corporation (the “Board”) the Optionee’s duties and responsibilities assigned by the Board which failure continues, in the reasonable judgment of the Board, after written notice given to the Optionee by the Board; (iv) gross
negligence, willful misconduct or insubordination by the Optionee with respect to the Corporation or any affiliate or subsidiary of the Corporation; or (v) a violation of any provision of any agreement(s) between the Optionee and the
Corporation relating to noncompetition, nondisclosure and/or assignment of inventions. The Optionee shall be considered to have been discharged for Cause if the Corporation or any subsidiary determines, within thirty (30) days after the
Optionee’s resignation, that discharge for Cause was warranted. 

  
 2 

 4. Payment of Purchase Price. 

(a) Method of Payment. Payment of the purchase price for shares purchased upon exercise of this option shall be made: (i) by
delivery to the Corporation of cash or a check to the order of the Corporation in an amount equal to the purchase price of such shares, (ii) subject to the consent of the Corporation, by delivery to the Corporation of shares of Common Stock of
the Corporation then owned by the Optionee having a fair market value equal in amount to the purchase price of such shares, (iii) by any other means which the Administrator (as that term is defined in the Plan) determines are consistent with
the purpose of the Plan and with applicable laws and regulations (including, without limitation, the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 and Regulation T promulgated by the
Federal Reserve Board), or (iv) by any combination of such methods of payment. 
 (b) Valuation of
Shares or Other Non-Cash Consideration Tendered in Payment of Purchase Price. For the purposes hereof, the
fair market value of any share of the Corporation’s Common Stock or other non-cash consideration which may be delivered to the Corporation in exercise of this option shall be determined in good faith by
the Administrator. 
 (c) Delivery of Shares Tendered in
Payment of Purchase Price. If the Optionee exercises this option by delivery of shares of Common Stock of the Corporation, the certificate or certificates representing the shares of Common Stock
of the Corporation to be delivered shall be duly executed in blank by the Optionee or shall be accompanied by a stock power duly executed in blank suitable for purposes of transferring such shares to the Corporation. Fractional shares of Common
Stock of the Corporation will not be accepted in payment of the purchase price of shares acquired upon exercise of this option. 
 (d)
Restrictions on Use of Option Stock. Notwithstanding the foregoing, no shares of Common Stock of the Corporation may be tendered in payment of the purchase price of shares purchased upon exercise of this option if the shares to be so tendered
were acquired within twelve (12) months before the date of such tender through the exercise of an option granted under the Plan or any other stock option or restricted stock plan of the Corporation. 

5. Delivery of Shares; Compliance With Securities Laws,
Etc. 
 (a) General. The Corporation shall, upon payment of the option price for the number of shares purchased and paid
for, make prompt delivery of such shares to the Optionee, provided that if any law or regulation requires the Corporation to take any action with respect to such shares before the issuance thereof, then the date of delivery of such shares shall be
extended for the period necessary to complete such action. 
 (b) Listing, Qualification, Etc. This option shall be subject to the
requirement that if, at any time, counsel to the Corporation shall determine that the listing, registration or qualification of the shares subject hereto upon any securities exchange or under any state or federal law, or the consent or approval of
any governmental or regulatory body, or that the disclosure of non-public information or the satisfaction of any other condition is necessary as a condition of, or in connection with, the issuance or purchase
of shares hereunder, this option may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or 

  
 3 

 
approval, disclosure or satisfaction of such other condition shall have been effected or obtained on terms acceptable to the Administrator. Nothing herein shall be deemed to require the
Corporation to apply for, effect or obtain such listing, registration, qualification or disclosure, or to satisfy such other condition. 

6. Nontransferability of Option. Except as provided in paragraph (e) of Section 3, this option is personal and no
rights granted hereunder may be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) nor shall any such rights be subject to execution, attachment or similar process, except that this option may be
transferred: (i) by will or the laws of descent and distribution or (ii) pursuant to a qualified domestic relations order as defined in Section 414(p) of the Code. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise
dispose of this option or of such rights contrary to the provisions hereof, or upon the levy of any attachment or similar process upon this option or such rights, this option and such rights shall, at the election of the Corporation, become null and
void. 
 7. No Special Employment or Similar Rights. Nothing contained in the Plan or this option shall be construed or deemed by any
person under any circumstances to create or to bind the Corporation or any subsidiary to enter into or continue any relationship (whether employment, independent contractor, agency, or other) of the Optionee with the Corporation or any subsidiary
for the period within which this option may be exercised. 
 8. Rights as a Shareholder. The Optionee shall have no rights as a
shareholder with respect to any shares which may be purchased by exercise of this option (including, without limitation, any rights to receive dividends or non-cash distributions with respect to such shares)
unless and until a certificate representing such shares is duly issued and delivered to the Optionee. No adjustment shall be made for dividends or other rights for which the record date is prior to the date such stock certificate is issued. 

9. Adjustment Provisions. 

(a) General. In the event of a merger, consolidation, sale of all or substantially all of the securities or assets, or reorganization,
recapitalization, etc. the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to an appropriate adjustment of the shares to be issued pursuant to this option. 

(b) Administrator Authority to Make Adjustments. Any adjustments under this Section 9 will be made by the Administrator, whose
determination as to what adjustments, if any, will be made and the extent thereof will be final, binding and conclusive. No fractional shares will be issued pursuant to this option on account of any such adjustments. 

10. Mergers, Consolidation, Distributions, Liquidations Etc. In the event of a merger, consolidation, distribution, liquidation or
other similar event, the Optionee shall, with respect to this option or any unexercised portion hereof, be entitled to the rights and benefits, and be subject to the limitations, set forth in Article 9 of the Plan. 

11. Withholding Taxes. The Corporation’s obligation to deliver shares upon the exercise of this option shall be subject to the
Optionee’s satisfaction of all applicable federal, state and local income and employment tax withholding requirements. 

  
 4 

 12. Investment Representations, Legends. 

(a) Representations. The Optionee represents, warrants and covenants that: 

(i) Any shares purchased upon exercise of this option shall be acquired for the Optionee’s account for investment only,
and not with a view to, or for sale in connection with, any distribution of the shares in violation of the Securities Act of 1933 (the “Securities Act”), or any rule or regulation under the Securities Act. 

(ii) The Optionee has had such opportunity as it has deemed adequate to obtain from representatives of the Corporation such
information as is necessary to permit the Optionee to evaluate the merits and risks of his investment in the Corporation, 

(iii) The Optionee is able to bear the economic risk of holding such shares acquired pursuant to the exercise of this option
for an indefinite period. 
 (iv) The Optionee understands that: (A) the shares acquired pursuant to the exercise of
this option will not be registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act; (B) such shares cannot be sold, transferred or otherwise disposed of unless they arc
subsequently registered under the Securities Act or an exemption from registration is then available; (C) in any event, an exemption from registration under Rule 144 or otherwise under the Securities Act may not be available for at least two years
and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Corporation is then available to the public, and other terms and conditions of Rule 144 are complied with; and
(D) there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Corporation and the Corporation has no obligation or current intention to register any shares acquired pursuant to
the exercise of this option under the Securities Act. 
 (v) The Optionee agrees that, if the Corporation offers any of his
Common Stock for sale pursuant to a registration statement under the Securities Act, the Optionee will not, without the prior written consent of the Corporation, directly or indirectly offer, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any shares purchased upon exercise of this option, for such period not to exceed (a) one hundred eighty
(180) days following the effective date of the relevant registration statement filed under the Securities Act in connection with the Company’s initial public offering of Registrable Securities, or (b) ninety (90) days following the
effective date of the relevant registration statement in connection with any other public offering of Registrable Securities; provided, however, that all officers and directors of the Company and all one percent (1%) percent or greater
stockholders of the Company enter into similar agreements. 
 By making payment upon exercise of this option, the Optionee shall be deemed
to have reaffirmed, as of the date of such payment, the representations made in this Section 12. 

  
 5 

 (b) Legends on Stock Certificate. All stock certificates representing shares of
Common Stock issued to the Optionee upon exercise of this option shall have affixed thereto legends substantially in the following forms, in addition to any other legends required by applicable state Law: 

“The shares of stock represented by this certificate have not been registered under the Securities Act or 1933 and may not be
transferred, sold or otherwise disposed of in the absence of an effective registration statement with respect to the shares evidenced by this certificate, filed and made effective under the Securities Act of 1933, or an opinion of counsel
satisfactory to the Corporation to the effect that registration under such Act is not required.” 
 “The shares of stock
represented by this certificate are subject to certain restrictions on transfer contained in an Option Agreement, a copy of which will be furnished upon request by the, issuer.” 

13. Miscellaneous. 
 (a)
Except as provided herein, this option may not be amended or otherwise modified unless evidenced in writing and signed by the Corporation and the Optionee. 

(b) All notices under this option shall be mailed or delivered by hand or overnight courier to the parties at their respective addresses set
forth beneath their names below or at such other address as may be designated in writing by either of the parties to one another. 
 (c)
This option shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts. 
 Page 6 Ends Here.

  
 6 

 DATED: Effective as of the Date of Grant. 

 

									
		 		 		 	   AURA BIOSCIENCES, INC.

 

									
	Dated:	 		 		 	By:	 	 

									
		 		 		 	 Elisabet de los Pinos, Ph.D.

President & CEO
 Hereunto Duly Authorized

 OPTIONEE’S ACCEPTANCE 

The undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges
receipt of a copy of the Corporation’s Amended and Restated 2009 Stock Option and Restricted Stock Plan. 
  

					
		 		 	OPTIONEE
			
	Dated:	 		 	  

		 		 	[NAME]
			
		 		 	Address:

  
 7 

 EXHIBIT 1 

Notice of Option Exercise 
 Date: 

TO: The Treasurer of AURA BIOSCIENCES, INC.: 

The undersigned, in accordance with the provisions of a Stock Option Agreement (“Agreement”) between AURA BIOSCIENCES, INC.
(“Corporation”) and the undersigned, hereby gives notice pursuant to Section 3(b) of the Agreement of the undersigned’s exercise of the option pursuant to the Agreement to purchase
(#)                    common shares of the Corporation for the aggregate payment for said shares of
$                     (“Price”) payable as follows (please check one): 

 

			
	☐    	 	by the tender of a check for immediately available funds for the entire Price (enclose check made payable to “AURA BIOSCIENCES, INC.”);
		
	☐	 	subject to the consent of the Corporation, by tendering (#)                    shares of the Corporation’s
(type)                    stock;
		
	☐	 	subject to the consent of the Corporation, by tendering $                    in cash (enclose check made payable to
“AURA BIOSCIENCES, INC.”) and                      shares of the Corporation’s
(type)                    stock; or
		
	☐	 	by alternative means approved by the Corporation’s Administrator as follows:
		 	  

		 	  

		 	  

 The undersigned represents and warrants to the Corporation that all of the representations and
warranties set forth in Section 12(a) of the Agreement are true and correct as of the date of this Notice. 
  

			
	Signature:	 	 

 
			
		
	Name:	 	

 
			
		
	Address:	 	

 
			
	
	Social Security Number:

  
 Exhibit 1 – 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]